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Abstract 
 
Reversible modifications of redox sensitive protein thiols by reactive oxygen and nitrogen 
species have emerged as a major posttranslational mechanism that affects the function of the 
respective proteins and therewith all downstream events. These modifications can be reversed 
by redox catalysts of which the thioredoxin system forms one of the most prominent. It is 
ubiquitously expressed and consists of thioredoxin reductase (TrxR) that takes electrons from 
NADPH to reduce thioredoxin (Trx) as well as a myriad of other substrates. Within this thesis 
we have studied several aspects of cellular signaling pathways modulated by the Trx system. 
 
Paper I. The Trx system is overexpressed in many types of cancers and considered to 
contribute to their survival by countering elevated ROS levels that are typical for these cells. 
Thus, inhibiting TrxR in order to attenuate the antioxidant capacity of cancer cells might tip the 
balance in favor of ROS induced cell death pathways as a principle of cancer therapy. TrxR1 is 
a particularly suitable target in this context due to its highly reactive and accessible 
selenocysteine (Sec) residue within its C-terminal active site. At physiological pH the Sec is 
mostly de-protonated and thus easily targeted by electrophilic compounds. In characterizing 
Au, Pt and Pd based salts we found that all inhibited the Sec-depended activity of the enzyme in 
a specific manner, with Au and Pd being more potent than Pt in vitro. In context of cellular 
TrxR1, however, inhibition and cytotoxicity were mainly dependent on the ligand substituents 
of the compounds and thus their cellular uptake and metabolism. We furthermore discovered 
cisplatin triggered covalent complex formation of TrxR1 with either Trx1 or TRP14 
(thioredoxin like protein of 14 kDa), which potentially contributes to the mechanism of 
cisplatin mediated cytotoxicity. 
Paper II. TrxR1 has in addition to its main isoform at least five minor splice variants that are 
distinguished by their N-terminal extensions. These may directly influence the activity of the 
TrxR1 core module or mediate subcellular localization via potential translocation signals. One 
of these variants, named “v3” (carrying a unique glutaredoxin domain), was previously shown 
to associate with the plasma membrane where it provoked dynamic filopodia. Within this study 
we found that v3 associates with specific membrane raft microdomains upon N-myristoylation 
and palmitoylation. These membrane structures were shown to serve as signaling platforms, 
including redox dependent processes, suggesting that v3 is potentially involved in redox 
signaling. 
Paper III. Transcription factors are a specific group of proteins that regulate the rapid 
transcription of genes. Many are functionally intertwined, activated under redox perturbing 
conditions and highly controlled by regulatory networks like the thioredoxin and glutathione 
systems. Signaling pathways leading to their activation are complex and expected to be 
modulated by numerous factors. In order to simultaneously characterize several transcription 
factors on single cell level we developed a method that is based on a three-colored 
fluorescence-based reporter plasmid (pTRAF). We demonstrated the use by quantifying 
responses of the three medically important transcription factors Nrf2, HIF and NFB, utilizing 
HEK293 cells that were subjected to diverse stimulants. 
 
In conclusion, we studied TrxR1 targeting by noble metal based compounds and characterized 
their ability to transform TrxR1 into its pro-oxidant SecTRAP form as a principle of anti-cancer 
therapy. We also identified the mechanism behind the intracellular localization of “v3” and 
show that it is targeted to lipid rafts where it is a potentially important regulator of signaling 
processes. Finally we developed a tool to study the activation of three redox sensitive, 
intertwined transcription factors.    
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1 Introduction 
 
The overall aim of research in redox biology is to understand the coordination, 
regulation and final consequence of electron flows in living organisms as well as their 
general organization. As such, it is at the heart of life science and touches almost all 
areas of biology covering aspects like selenium and sulfur chemistry, oxidative stress, 
metabolism, free radicals and signaling1-4.  
 
Its centrally relevant elements are reduction-oxidation (redox) reactions that modify 
cellular components by either increasing or decreasing their oxidation state, which in 
turn modulates their respective functions. The realization that especially thiol groups of 
cysteine residues are redox sensitive and that their modifications are major 
posttranslational regulators of protein function changed the view to the current 
understanding that these transient processes are as important and as common as 
phosphorylation (Fig. 1).  
 
Over the last decades it has been recognized that reactive oxygen and nitrogen species 
(ROS, RNS) as well as a number of other reactive molecules operate as second 
messengers in redox pathways. Hydrogen peroxide (H2O2) is among all species the 
most relevant in the context of cell signaling. Several studies suggest that the 
production, diffusion and life time of ROS in general, and H2O2 in particular, is a 
tightly regulated and highly complex process. But despite its eminent importance, the 
exact mechanism behind the regulation of specific and efficient oxidation in redox 
signaling is still not fully understood (Fig. 1a).  
 
The mechanisms to reverse these oxidative modifications are slightly better 
characterized, but numerous questions still remain before a thorough understanding of 
this complex processes can be achieved. The two most prominent systems in this 
context are the glutathione (GSH) and the thioredoxin (Trx) systems with the latter 
being the focus of this thesis. Both employ coupled redox active enzymes to constantly 
reduce their respective intracellular substrates. These systems are essential regulators 
for a myriad of cellular processes as well as for antioxidant defense and redox 
homeostasis (Fig. 1b).     
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Figure 1. Principle regulation of thiol proteins via the interplay of oxidation and reduction 
pathways. a) ROS mediated thiol oxidation (SOx) can affect a number of different processes such 
as transcriptions factor activities, protein interaction or enzyme activities. b) These modifications, 
and thus their effects on the protein, can be reversed by reducing enzyme systems such as the 
GSH or the Trx system. The cooperation of oxidizing and reducing mechanisms regulates the 
function of thiol proteins and thus the respective pathways.   
 
The overall aim of this thesis was to further understand how the thioredoxin system is 
involved redox regulation. For this we concentrated our efforts on the following three 
distinct aspects:   
 
Paper I The thioredoxin system as target in anti-cancer therapy.  
 
Paper II Compartmentalization of the “v3” splice variant of TrxR1 and 
effects on cell motility.  
 
Paper III Developing a method to analyze the activation of redox sensitive 
transcription factors on single cell level. 
 
The following chapters aim to briefly introduce some of the key aspects in redox 
regulation and signaling: I) reactive species in redox signaling, II) reducing enzymes 
with a focus on the thioredoxin system, III) redox modifications of thiols and IV) redox 
regulated transcription factors.   
e  Donor
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2 Reactive species in biological systems 
 
2.1 Introduction  
 
Reactive oxygen species (ROS) and oxidative stress 
 
Reactive oxygen species (ROS) refers to a group of reactive intermediates that are 
formed during incomplete oxygen reduction (see chapter 2.2 for more details). They 
are produced under non-stressed conditions and in response to various stimuli. At low 
concentrations, ROS are essential and have been shown to function as second 
messengers in the regulation of many physiological processes including the 
activation/deactivation of transcription factors and enzymes or the modulation of 
calcium-dependent and phosphorylation pathways5-8. At high and unbalanced 
concentrations however, ROS can inflict damage to cellular constituents causing fatal 
alterations and eventually cell death. This condition is commonly referred to as 
oxidative stress and associated with several severe conditions such as diabetes, 
atherosclerosis, cancer and neurodegenerative disorders9-13 (Fig. 2).  
 
Figure 2. Oxidative stress in the development of diseases. The balance between ROS and 
antioxidant systems is essential for normal cell function and redox homeostasis. Disruption is 
referred to oxidative stress and affects the cell in numerous ways depending on the degree of the 
imbalance. Small to moderate levels of oxidative stress have been shown to stimulate stress 
responses that lead to cell proliferation and the activation of survival pathways. If prolonged, this 
condition can alter cellular processes and promote the development of diseases. The continued 
increase of oxidative stress exceeds at some point the beneficial effects, causing extensive 
oxidative damage that eventually leads to cell death. Therapeutic approaches in most oxidative 
stress related conditions, with the exception of cancer, is thus typically based on either boosting 
the antioxidant capacity or in inhibiting the source of ROS production14-16.  
 
Homeostasis
Proliferation
Signaling
Normal 
functions
Oxidative stress/
Imbalance of oxidants 
and antioxidant systems
Cell death
Treshold
Health Disease
Transcription factors
Antioxidant systems
DNA repair
Survival factors
Stress response Oxidative damage
Compromised host defence
Mutations/ promotion of carcinogenesis
Impaired redox signaling/ regulation 
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ROS are thought to exert their physiological function via site-specific, covalent 
modifications of proteins to modulate the enzymatic activity, folding or intracellular 
location of those. Particularly the cysteine residues in these proteins, which are often 
essential for proper protein function, can be easily oxidized and are thus suitable targets 
for signal transmission and regulation17, 18. 
 
Reactive nitrogen species (RNS)  
 
Reactive nitrogen species (RNS) are reactive molecules that are equally important 
second messengers in redox signaling pathways. They have been shown to modify thiol 
groups by the incorporation of nitric oxide in a process termed S-nitrosylation. The 
exact chemistry behind S-nitrosylation in vivo is still not completely clear, but it was 
shown that this modification can affect redox sensitive pathways by modulating the 
activity of transcription factors such as HIF and NFB19, 20, of proteases like MMP-921 
or of caspases22, 23. The predominant variant is nitric oxide (•NO), which was shown to 
regulate various processes including vasodilation/ relaxation24, 25 and 
neurotransmission26, 27 as well as proliferation, apoptosis and host defense28. •NO can 
be metabolized to other reactive forms that may participate in redox signaling and 
contribute to RNS associated physiological and pathological conditions (see chapter 
2.2).  
 
Reactive sulfur species (RSS)  
 
Occasionally a third group consisting of reactive sulfur species (RSS) is considered in 
redox signaling processes based on the concept that these reactive sulfur intermediates 
are capable of propagating their redox modifications analogous to ROS and RNS29, 30. 
This group includes amongst others oxidized thiol groups such as disulfides, sulfenic 
acid or S-nitrosothiols31, 32, but also inorganic sulfur-containing species like 
hydrogensulfide (H2S) or thiocyanate (SCN -)33-35. Particularly H2S has been discussed 
in redox signaling and is considered to function similar to carbon monoxide (CO) or 
•NO as a physiological vasorelaxant36-38. Another example is the concept of targeted 
protein oxidation via oxidized peroxiredoxin intermediates (further discussed in chapter 
3.3)39. The overall physiological significance of RSS is however, not well established 
and thus not discussed in detail within this thesis31, 36, 40. 
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2.2 Formation 
 
The following chapters aim to provide an overview on the formation and reactivity of 
ROS and RNS with a focus on biologically relevant molecules in the context of redox 
signaling. A general overview is provided in Figure 3.    
 
Figure 3. Metabolism of reactive oxygen and nitrogen species. A) Superoxide formation via 
electron transfer as either by-product or volitional. Subsequent dismutation to hydrogen peroxide 
(H2O2) and oxygen is performed by superoxide dismutases (SODs). H2O2 in turn is either i) 
removed by catalase, peroxiredoxin or glutathione peroxidase, ii) used to produce hypochlorous 
acid (HOCl) in phagosomes by myeloperoxidases to facilitate efficient killing of engulfed bacteria 
or iii) involved in hydroxyl radical (•OH) formation together with O2•
- via Fenton and Haber-Weis 
chemistry. B) Nitric oxide (•NO) formation is mediated by •NO synthases enzymes (NOSs). It is 
subsequently autoxidized to nitrite (NO2
-
) and nitrate (NO3
-
), but can potentially be reduced to •NO 
again. Via reaction with molecular oxygen •NO can be transformed to the nitrogen dioxide radical 
(•NO2) and subsequently to dinitrogen trioxide (N2O3) by radical coupling with •NO. Additionally, 
peroxynitrite (ONOO
-
) can be formed in the presence of superoxide. Color intensity correlates to 
the relative reactivity. The figure was modified from Paulsen and Carroll, 201340. 
 
 
Reactive oxygen species 
 
Out of all reactive oxygen species, H2O2 is the most suitable in terms of redox 
signaling. It is only mildly reactive, has a long half life (  1 ms), shows selective 
reactivity and can diffuse through membranes either freely or via aquaporins8, 41-44. 
Overall cellular concentrations are in the nanomolar to low micromolar range and 
constantly regulated by the antioxidant enzymes glutathione peroxidases (GPxs), 
peroxiredoxins (Prxs) and catalase41, 42. Direct H2O2 production is only facilitated by a 
handful of oxidases such as glucose-, xanthine-, lysyl-, monoamine-, and D-amino 
acid-oxidases, which are yet mostly uncharacterized in terms of redox signaling45-47. 
The majority of H2O2 however, is produced in rapid dismutation reactions of 
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superoxide (O2•-) to H2O2 either spontaneous (  1 5 M-1 s-1) or facilitated by superoxide 
dismutases (SODs) (  1 9 M-1 s-1)48, 49. Cellular O2•- concentrations are thus merely in 
the low picomolar range despite the constant formation as by-products of respiration at 
the mitochondria42, 50 and during the catalytic activities of enzymes51-55. Mitochondrial 
O2•- formation is estimated to be 0.15 – 2% of all consumed oxygen. Under normal 
conditions this output is tightly regulated by several antioxidant systems56-58 and 
facilitates regulation of various redox sensitive pathways including inflammatory 
responses59-61, autophagy62, HIF activation63-65 or metabolic feedback regulation66. 
 
Unlike the aforementioned sources, O2•- and thus H2O2 is deliberately produced by 
NADPH oxidases (NOXs) in response to various forms of cell stress and stimuli67, 68 
for the propose of activating redox sensitive signaling pathways, including transcription 
factor activation, PTP inhibition, ion channel activation or regulation of enzyme 
activities69, 70. The NOX family comprises in total seven core members (NOX 1-5, 
Duox1 and Duox2) that are expressed in a distinct cell type and tissue specific 
manner69, 71. These enzymes are evolutionarily conserved multisubunit complexes that 
require the translocation and assembly of several cofactors and activators in order to 
function69, 72-76. These factors are regulated and display stimulation and cell type 
dependent intracellular localization and activation patterns as a means of specific, 
regulated H2O2 formation. NOX activity has been reported to localize to the ER77-79 and 
the nucleus80, 81 as well as to various specific membrane compartments such as lipid 
rafts82, focal adhesions83, activated receptors72, 84 or invadopodia85.  
 
Superoxide is indirectly important for redox signaling processes via the formation of 
H2O2, but unlikely to be involved in direct thiol oxidation. Rate constants are typically 
below 103 M-1 s-1 and thus far outcompeted by dismutase reactions86, 87. Only iron-
sulfur proteins could react fast enough with superoxide, but this leads to their inhibition 
and is typically associated with O2•- toxicity88. Likewise, other ROS variants are 
unsuitable for signaling purposes based on their high reactive and indiscriminate choice 
of reaction partners41.   
 
Some of these highly reactive variants include hypochlorous acid (HOCl) and hydroxyl 
radicals (•OH). HOCl formation from H2O2 is catalyzed by myeloperoxidases in 
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neutrophil phagosomes to facilitate efficient killing of engulfed bacteria89, 90. HOCl can 
additionally react with O2•- to produce the hydroxyl radical (•OH), which also 
contributes to the activity of neutrophils91. Hydroxyl radicals can furthermore be 
formed via Fenton and Haber-Weiss chemistry under conditions were trace metal ions 
are available31. Particularly •OH is very reactive and formation is thus strongly 
restricted under normal conditions92.   
 
Reactive nitrogen species 
 
Nitric oxide (•NO) is the prototypic reactive nitrogen species (RNS) and was the first 
reactive molecule to be recognized as second messenger, with Furchgott, Murad and 
Ignarro getting the Nobel Prize in Physiology or Medicine in 1998 for this discovery25 . 
Overall physiological concentrations are estimated to be in the range of 100 pM to 5 
nM with a half-life of approx. 0.1 to 2 s93, which reflects its modest reactivity compared 
to H2O2. It can freely diffuse through membranes94 and thus function as paracrine, 
autocrine and endocrine signal within a 200 M radius95, 96. •NO formation is catalyzed 
by three distinct nitric oxide synthase (NOS) isoforms – endothelial NOS (eNOS), 
inducible NOS (iNOS) and neuronal NOS (nNOS)97-99. eNOS and nNOS express •NO 
constitutively in a Ca2+ dependent manner in contrast to iNOS, whose activity is Ca2+  
independent and regulated by cytokines and interleukins100. Regulation of these and 
thus of •NO formation is complex and reviewed elsewhere in detail40.  
 
The main cellular targets for •NO are other reactive species such as superoxide or 
metals. A prominent example is reversible binding to the heme in soluble guanylyl 
cyclase, which activates the enzyme to stimulate vasodilation101. The reaction with O2•- 
on the other hand promotes the formation of peroxynitrate (ONOO-) with rate constants 
of 1010 M-1 s-1 that even exceed SOD catalyzed dismutation reactions. Peroxynitrate is 
highly reactive and damages cellular components. Its production is often associated 
with a number oxidative stress related conditions such as cardiovascular, 
neurodegenerative and inflammatory diseases102.  
 
•NO can furthermore autooxidize to either nitrite (NO2-) or nitrate (NO3-). These 
variants have mainly been considered as by-products, but are also discussed in •NO 
signaling based on the existence of enzymes such as xanthine oxidase103 or 
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deoxyhemoglobin104 that are capable of reducing NO2- to •NO again. •NO can 
additionally react with molecular oxygen to form nitrogen dioxide (•NO2) that is further 
converted to dinitrogen trioxide (N2O3) by radical-radical interaction with a second •NO 
molecule105. N2O3 in turn can directly S-nitrosylate thiolate groups in proteins or low 
molecular weight compounds. This might however, be only relevant at higher 
concentrations of •NO as this process is limited by dinitrogen trioxide formation. 
Alternatively, •NO might S-nitrosylate a thiyl radical that was initially formed during 
one-electron oxidation of a thiolate group by radicals such as •NO or O2•-106, 107.  
 
An interesting property of •NO mediated modifications is the ability to transfer this 
modification to another thiolate in a process called transnitrosylation. The reaction of 
GSH with an S-nitrosothiol for example can result in a free thiol and GSNO. GSNO in 
turn can be reduced by GSNO reductase to give GSH and HNO108. S-nitrosylated low 
molecular weight thiols such as GSNO or S-nitroso-L-cysteine (L-CysSNO) are 
furthermore able to S-nitrosylate other protein thiols and thus frequently used in S-
nitrosylation studies.    
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2.3 Antioxidants and redox regulatory enzymes 
 
Introduction 
 
Cells utilize a variety of low molecular weight antioxidants, antioxidant enzymes and 
repair systems to protect against oxidative damage, but also to reverse oxidative 
modifications in order to regulate signaling pathways109. The composition varies 
between tissues and cells and is affected by nutrition and cellular redox states. Some of 
the well known non-enzymatic antioxidants include Vitamin A and E, ascorbate, lipoic 
acid, ubiquinone and GSH41. Their functionality and intracellular localization is 
variable, but involves essentially the scavenging of highly reactive radicals or the 
chelation of transition metal ions. They may also be either directly or indirectly 
regenerated by various antioxidant enzymes with the GSH and Trx systems being 
considered the most important. The latter is central to this thesis and thus discussed in 
more detail in chapter 3.  
 
Figure 4. Illustration of the GSH and Trx systems. The Trx system has a diverse set of 
functions as illustrated further in chapter 3. Its key enzyme is TrxR that takes electrons from 
NADPH to reduce Trx as well as a number of other substrates. The GSH system fulfills similar 
functions. At its core is GSH that is used as cofactor for GST, GPx and Grx, but also acts directly 
in a number of processes.   
 
Glutathione system 
 
The tripeptide glutathione (GSH; Glu-Cys-Gly) is present in low millimolar 
concentrations and thus the most abundant low molecular weight antioxidant109, 110. It 
can scavenge electrophilic and oxidizing compounds either directly or catalyzed by 
glutathione-S-transferases (GSTs), which has also been shown to be important in the 
modulation of signaling pathways111, 112. Additionally, GSH is used as a cofactor by 
glutathione peroxidases (GPxs) to reduce hydroperoxides and by glutaredoxins (Grxs) 
that operate as disulfide reductases and de-glutathionylation enzymes113 (Fig. 4).  
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After donating the electrons, two GSH molecules form a glutathione disulfide (GSSG) 
via an intermolecular disulfide bridge. This oxidized form is in turn reduced by 
glutathione reductase (GR), which uses NADPH as electron donor114. Interestingly, 
GSH also influences redox signaling events via glutathionylation of reactive thiol-
groups in key cysteine residues. This protects them from oxidative modifications and 
electrophilic compounds115. 
 
The glutathione peroxidase (GPx) family contains eight isoforms that are expressed in 
various tissues and with different subcellular localizations. GPx1-4 and GPx6 in 
humans have a peroxidatic Sec residue whereas the other isoforms contain a Cys 
instead. GPx4 is unique as it can also reduce hydroperoxides in complex lipids such as 
phospholipids or cholesterol. In addition to being important antioxidant enzymes they 
are also discussed in redox signaling and the regulation of physiological processes. An 
interesting example is given by the currently discussed GPx7 and GPx8 isoforms. Both 
reside in the endoplasmatic reticulum and have shown to be able to transfer their 
oxidation state to PDI in vitro. This was previously demonstrated for Prx4 and is 
considered an important process for targeted oxidation116. The GPx family was recently 
reviewed in detail by Brigelius-Flohé and Mairino117. 
 
Peroxiredoxins  
 
Peroxiredoxins (Prxs) form an important antioxidant and redox regulatory enzyme 
family that contain several protein isoforms (Prx1-6) that differ in their cellular 
localization, substrate specificity and reaction mechanism (Table 1). For a long time 
they have only been discussed in the prevention of oxidative stress by reducing 
hydrogen peroxide, organic hydroperoxides, lipid hydroperoxides and peroxinitrite. 
However, the realization that hydroperoxides are important mediators of physiological 
processes brought about a change of view. Now their roles are increasingly discussed in 
the context of signal transduction by either regulating the concentration of 
hydroperoxidic mediators and thus the respective signaling pathways or by acting as 
sensors that may transfer an oxidative modification to a specific target protein via 
protein-protein interaction. The peroxiredoxin enzyme family has been extensively 
discussed in these recent reviews118, 119.   
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Table 1. Localization and general catalytic mechanism of peroxiredoxins (Prxs). All 
peroxiredoxins form anti-parallel homodimers. Localization and expression is dependent on cell 
type and the environment. Prx5 and 6 are less sensitive to overoxidation, but the overoxidized 
forms are not reduced by sulfiredoxin. The main function is the reduction of hydrogen peroxide, 
organic peroxides, lipid peroxides and peroxynitrite, but they have also been discussed in 
oxidizing other thiols.   
 
 
Additional antioxidant enzymes 
 
Many of the antioxidant enzymes have very distinct functions and exhibit high reaction 
rates. The aforementioned superoxide dismutases for example, specialize in the rapid 
dismutation of superoxide to the less reactive hydrogen peroxide. The regulation of 
superoxide levels is essential since it can either react with nitric oxide to form the 
highly reactive peroxynitrite or hydroxyl radicals via the Fenton reaction (Fig. 3). 
Mammalian cells contain two variants: MnSOD (SOD2) that is located in the matrix of 
the mitochondria and the predominantly cytosolic CuZnSOD (SOD1), which can also 
be found in the nucleus, lysosomes and the intermembrane space of the 
mitochondria120. Catalase is another antioxidant enzyme that however, specializes on 
the decomposition of hydrogen peroxide to water in peroxisomes121. Other than 
controlling the levels of reactive molecules, some enzymes are specialized on the 
reversal of damaging oxidative modifications. The enzyme family of methionine 
sulfoxide reductases (Msrs) is for example able to reduce oxidized methionine 
residues122. Another repair enzyme is sulfiredoxin that is able to reduce sulfinic acid 
back to sulfenic acid in a subset of peroxiredoxins123. 
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3 The thioredoxin system 
 
The thioredoxin system is one of the key redox regulatory systems in the cell and as 
such involved in defense against oxidative stress124, 125, cell proliferation and viability16, 
126 as well as protein folding and signal transduction127, 128. It consists of thioredoxin 
reductase (TrxR) that uses NADPH as electron donor to reduce its main substrate 
thioredoxin (Trx)129, 130, which in turn sustains a number of pathways by either 
providing enzymes with electrons or via protein-protein interactions16, 125 (Fig. 4). TrxR 
furthermore catalyzes the reduction of various additional thiol-proteins as well as 
several low-molecular weight compounds and thus displays a functional spectrum that 
exceeds the mere reduction of Trx131. In mammals these functions are essentially 
carried out by cytosolic TrxR1/Trx1 and mitochondrial TrxR2/Trx2 isoenzymes. 
 
Its central functions in redox regulation and antioxidant defense link the thioredoxin 
system to numerous pathophysiological conditions that are related to an oxidative 
imbalance and thus identify it as a promising therapeutic target. Conditions such as 
cardiovascular and neurodegenerative diseases, inflammation and those related to aging 
are often associated with elevated ROS levels while having a low antioxidant capacity 
and might therewith be countered by boosting the thioredoxin system16, 132. However, a 
high antioxidant activity might on the other hand also be unfavorable in some cases 
such as certain types of cancer where it promotes proliferation and associates with 
resistance to chemotherapy and a poor patient prognosis. Particularly TrxR is discussed 
as a potential anti-cancer target due to its central role in the Trx system and as a prime 
target for electrophilic drugs133, 134. 
 
A more comprehensive overview with regard to the physiologic importance is provided 
by the recent reviews of Mahmood et al.16 and Lu et al.125.  
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3.1 Thioredoxin and the thioredoxin fold family of proteins 
 
Trxs are 12-kDa large oxidoreductases that typically catalyze thiol-disulfide exchange 
reactions via their conserved -CGPC- active site motif127. They are ubiquitously 
expressed and characterized by a specific structure that consists of a four-stranded beta 
sheet surrounded by three alpha helices135-137. Variations of this so called Trx fold are 
also part of Grxs138  and Prxs139 as well as GPxs140, GSTs141 and protein disulfide 
isomerases (PDIs)142 – all of which were shown to exhibit oxidoreductase activity. Trx 
fold proteins are further characterized by their active site motif – containing either one 
or two cysteine residues together with different adjacent amino acid residues, resulting 
in different catalytic mechanisms. 
 
The main mammalian isoforms of Trx are the cytosolic Trx1 and the mitochondrial 
Trx2. Both are major disulfide reductases with various specific functions in redox 
regulation and antioxidant defense127 (Fig. 5). Trx1 has in contrast to Trx2 three 
additional cysteines that are suggested to be the subject of post-translational 
modifications such as glutathionylation, S-nitrosylation and disulfide formation that 
may contribute to its redox regulatory functions in different physiologic contexts143-146. 
The formation of a second disulfide bond between the non active site Cys62 and Cys69 
leads for example to an inactivated form that can not directly be reduced by TrxR1, but 
requires the Grx system instead147, 148. 
 
Trx1 is predominantly located in the cytosol where it provides RNR with electrons and 
catalyzes the reduction of Prxs149 and Msrs150. It can however, also translocate into the 
nucleus under oxidative conditions where it regulates gene expression by modulating 
the binding of various transcription factors to DNA including NFB, HIF, p53, Nrf2, 
AP-1 and the glucocorticoid receptor151-158. Furthermore, reduced Trx1 directly binds 
PTEN, which is a major tumor suppressor that prevents survival signaling by 
deactivating the PI3K/Akt pathway. Trx1 binding inhibits the phosphatase activity of 
PTEN and promotes thus cell proliferation and tumor growth while also inhibiting 
apoptosis159. Trx is also an important regulator of apoptosis signal regulating kinase 1 
(ASK1). In its reduced form Trx is binding and thus inhibiting ASK1. However, high 
levels of ROS promote oxidation of Trx and thus ASK1 release leading to subsequent 
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apoptosis160. ASK1 release may also be promoted by the Trx interacting protein 
(TXNIP), an endogenous inhibitor of Trx that binds to reduced Trx and thus competes 
with ASK1161. Interestingly TXNIP binding mediates also Trx1 translocation to the 
plasma membrane, which is proposed to enable inflammation in endothelial cells by 
promoting cell survival and vascular endothelial growth factor signaling during 
oxidative stress162. Additionally, Trx together with a truncated variant (Trx80) can be 
found in the extracellular environment where it exhibits an oxidoreductase independent 
chemokine-like activity109, 163.    
Figure 5. Substrates and principle functions of the thioredoxin system. Doted lines indicate 
direct binding whereas solid lines show thiol-disulfide exchange reactions. Oxidative stress 
promotes Nrf2 activation, which in turn induces Trx and TrxR expression. For further details see 
text. Figure was modified from Lu et al.164. 
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3.2 Thioredoxin reductases 
 
Classification and catalytic activity 
 
TrxRs are dimeric flavoenzymes that belong to the pyridine nucleotide disulfide 
oxidoreductase family, which also includes glutathione reductase131, 165. They exist in 
two forms: low-Mr TrxRs (ca. 35 kDa/ subunit) that can be found in lower eukaryotes 
and prokaryotes and high-Mr TrxRs (ca. 55 kDa/ subunit) that are present in higher 
eukaryotes166, 167. Low-Mr TrxRs contain one FAD and one redox active disulfide 
motif, but lack the additional C-terminal -XCU/CX active site that distinguishes the 
larger TrxR variants166, 168. The selenocysteine containing -XCUX motif is 
characteristic for most high-Mr TrxRs such as mammalian TrxRs, whereas the -XCCX 
motif containing TrxRs can be found in certain parasites and insects such as D. 
melanogaster169.   
 
The principle catalytic mechanism for mammalian TrxR has been extensively studied 
and involves the transfer of electrons from NADPH to the oxidized N-terminal 
disulfide motif via the enzyme bound FAD. The thereby reduced dithiol exchanges 
these electrons with the selenenylsulfide in the C-terminal active site of the other 
subunit to form a reduced selenolthiol motif that in turn facilitates reduction of most 
substrates such as Trx and DNTB170, 171 (Fig. 6A). Several substrates, including certain 
quinones do not require an intact Sec-residue and may be directly reduced via the N-
terminal C59/ C64 dithiol motif172. 
 
Nonetheless, the detailed analysis of the TrxR mediated catalysis is an ongoing process 
and essential to fully understand the underlying mechanisms. Important features that 
are currently discussed include the need for selenocysteine in the active site131, 173-175, 
the structure of the flexible C-terminal tail175, 176, the function of key amino acids in the 
TrxR/substrate interface or in the vicinity of the active site as well as the exact electron 
flow during catalysis175, 177. Recent studies showed for instance that the C-terminal 
amino acids 407-422 in TrxR1 form a “guiding bar” like structure that restricts the 
movement of the C-terminal and supports the electron transfer from the N-terminal 
dithiol to the C-terminal selenenylsulfide motif. This arrangement promotes Sec-
dependent catalysis while simultaneously restricting the direct reduction of substrates 
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via the N-terminus176. TrxR2 in contrast, is lacking this supporting “guiding bar” and 
allows for a greater access to the N-terminal active site, which in turn promotes 
alternative catalytic mechanisms, makes the enzyme less dependent on the Sec residue 
and influences its substrate specificity175. 
 
Figure 6. Principle electron flow in normal catalysis and differential modes of inhibition. A) 
Scheme of the head-to-tail homodimer confirmation of mammalian TrxR. The principle electron 
flow during normal catalysis is indicated. B) Targeting via electrophilic compounds can either leave 
the enzyme complete inactive (left) or transform it into its pro-oxidant SecTRAP form, which might 
lead to cell death via apoptosis and necrosis. Figure was modified from Anestål et al.178. See text 
for further details.     
 
TrxR inhibition and SecTRAP formation 
 
The Sec residue in the flexible C-terminal active site is easily accessible and highly 
reactive due to its strong inherent nucleophilicity. These properties are important for its 
catalytic efficiency; however, they also make its reduced selenolate form prone to 
attacks by electrophilic compounds131. The list of identified inhibitors is extensive and 
includes naturally occurring substances such as flavonoids179, 180, the lipid peroxidation 
product 4-hydroxy-2-nonenal (HNE)181 or curcumin182 as well as many constructed 
electrophilic compounds of which some are already in clinical use. Prominent examples 
include gold compounds (auranofin183, aurothioglucose184), platinum compounds 
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(cisplatin185, oxaliplatin186), arsenic oxide187, nitrosoureas188 or dinitrohalobenzenes189. 
Despite their overall similarity, TrxR1 and TrxR2 are differentially targeted by 
electrophiles. This might in part be due to their different intracellular localization, but it 
has also been shown that their inherent catalytic properties play a role as well175, 190.   
 
The effect of various inhibitors on the activity of TrxR1 is diverse – some diminish the 
enzymatic activity completely while others transform the enzyme into its pro-oxidant 
SecTRAP form (selenium compromised thioredoxin reductase-derived apoptotic 
protein)178, 191 (Fig. 6B). SecTRAPs are presumably formed by compounds that 
specifically derivatize the Sec residue. These enzymes have lost the ability to catalyze 
Sec dependent reactions, but gained a potent NADPH oxidase activity by being able to 
redox cycle with certain substrates via the intact FAD and N-terminus active site. 
Recent studies propose that the increased access to the N-terminus is promoted by 
conformational changes that are caused by the modification of the Sec residue175, 177. In 
the unmodified enzyme this access and thus electron leakage at the N-terminus is 
thought to be prevented by an efficient electron transfer to the Sec residue177.  
 
SecTRAPs were previously shown to induce cell death via apoptosis and necrosis and 
might thus contribute to the cytotoxic profile of many TrxR inhibitors178, 192-194. An 
interesting study showed for instance that A549 cells with high TrxR1 levels are more 
susceptible towards the SecTRAP forming compound cisplatin195 than A549 cells with 
low levels196. The same trend was illustrated in thiophosphate treated HCT116 and 
selenite treated NIH 3T3 cells. Selenite stimulated the expression of TrxR1 and 
rendered thus these cells more sensitive towards cisplatin, whereas thiophosphate on 
the other hand promoted a more resistant phenotype based on the stimulated expression 
of a less reactive, but also less sensitive Sec-to-Cys variant197. 
 
Transcriptional regulation and isoforms of human TrxRs 
 
Mammals possess three separate genes that guide the transcription of several isoforms. 
In human, the TXNRD1 gene encodes the predominantly cytosolic TrxR1129, whereas 
the mainly mitochondrial TrxR2 is expressed from the TXNRD2 gene198. A third 
isoenzyme, named thioredoxin glutathione reductase (TGR), can essentially be found in 
testis and is encoded by the TXNRD3 gene. TGR is unique as it contains an additional 
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monothiol glutaredoxin domain as N-terminal fusion to the TrxR core module199. It is 
mainly expressed in male germ cells and has been implicated in disulfide bond 
formation during sperm maturation200. 
 
The transcriptional regulation of TXNRD1 and TXNRD2 is complex and involves 
extensive alternative splicing yielding several mRNAs that in turn encode protein 
variants that differ in their N-terminal extensions131, 201. Most of these are minor 
variants and not extensively studied. Nonetheless, they might carry potential 
translocation signals and protein binding sequences and thus exhibit specific, localized 
functions or operate as back-up systems202, 203. Several splice variants of TXNRD2 
were, for example, shown to exhibit cytosolic expression patterns due to the lack of the 
mitochondrial targeting sequence in the 5’-end. They also showed a similar catalytic 
activity in the reduction of cytosolic Trx1 compared to mitochondrial Trx2, which 
indicates a potential back-up mechanism203, 204. Another example is given by the 
TXNRD1_v2 isoform of TrxR1, which contains an LQKLL nuclear receptor binding 
motif205. As a result, TXNRD1_v2 is translocated to the nucleus where it binds and 
regulates the estrogen receptors alpha and beta206.  
    
The TXNRD1_v3 isoform (“v3” in short) is among all splice variants of TrxR1 
particularly unusual as it contains an atypical glutaredoxin domain as N-terminal 
extension that is encoded by three 5’ exons located upstream of the TrxR1 core 
promoter. This unique constellation requires the activation of a yet uncharacterized 
alternative upstream promoter as well as a simultaneous shut-down of the TrxR1 core 
promoter during transcription205, 207, 208. The protein is predominantly expressed in the 
Leydig cells of the testis, but transcripts could also be detected in other tissues and in 
several cancer cell lines, where its expression could be induced by estradiol or 
testosterone treatment209. The glutaredoxin domain contains an atypical -CTRC-  active 
site motif that was shown to be inactive in typical Grx assays unless mutated to the 
more common -CPYC- active site found in Grxs208. Previous overexpression 
experiments of GFP-TXNRD1_v3 fusion proteins (either only the Grx domain or a 
Sec-deficient full length variant) in HEK293, Hela and MCF7 cells demonstrated an 
intracellular localization pattern that was characterized by a strong perinuclear 
localization as well as a dotted cytoplasmic and plasma membrane appearance. At the 
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membrane, GFP-TXNRD1_v3 co-localized with actin and induced dynamic cell 
protrusions that were later identified as filopodia209, 210. Also notably, the protein is only 
found in higher vertebrates like human, bovine, dog or chimpanzee, but not in rat or 
mouse208.  
 
All in all, the complex transcriptional regulation and the additional features of the 
variable N-terminal extensions are parameters that potentially contribute to the 
extensive spatial and temporal regulation of redox sensitive pathways.  
 
 
3.3 Thioredoxin reductases as targets for anticancer therapy 
 
Cancer collectively refers to a whole group of complex genomic disorders. In simple 
terms it can be viewed as the abnormal and uncontrolled proliferation of cells with an 
altered physiology. Although cancer types vary in several aspects, they often exhibit 
increased glycolysis, based on the need for energy to fuel their abnormal proliferation, 
as well as elevated ROS levels211, 212. ROS is not only a consequence of an increased 
cell metabolism, but has been implicated to be an essential factor in the development 
and progression of tumors as well213, 214. Moderately increased levels promote for 
instance the inactivation of the tumor suppressor PTEN215 and of several PTPs216 by 
oxidizing critical cysteine residues. Inhibition of PTPs in turn promotes the 
phosphorylation and activation of mitogen-activated protein kinase (MAPK) and 
extracellular signal-regulated kinase (ERK) pathways. These are only some examples 
by which cell survival and proliferation is stimulated by ROS217. 
 
Cancer cells typically also boost their redox regulatory and antioxidant capacities in 
parallel in order to balance the consistently high production of ROS and to avoid 
oxidative damage218 (Fig. 7). Inhibition of these cellular antioxidant systems might thus 
provide a therapeutic approach to promote cancer cell death via the rapid accumulation 
of ROS219, 220. 
 
 
 
 
 
 
Marcus Cebula 
 
20 
Figure 7. Redox homeostasis in normal and cancer cells. Normal cells have low levels of 
ROS, which are balanced by antioxidant systems. They also have a certain reserve capacity in 
order to buffer elevated ROS levels under stressed conditions and can thus prevent cell death. 
Cancer cells on the other hand, exhibit already elevated basal ROS levels that are balanced 
adequately by induced antioxidant systems. This balance is fragile however, as only a small 
reserve capacity is available before the threshold is reached. A decrease of the antioxidant 
capacity, for instance via chemotherapy that targets the antioxidant systems, might thus cause a 
massive accumulation of ROS and tip the balance in favor of cell death220. This approach of killing 
cancer might also be further amplified by stimulating an increase in ROS, which can be buffered 
by normal, but potentially not by cancer cells.      
 
The Trx system, particularly TrxR1, has been identified as a promising target for anti-
cancer therapy221. TrxR and Trx are both upregulated in numerous cancers with high 
Trx levels having been associated with aggressive cancers, poor patient prognosis and 
resistance to chemotherapy222, 223. TrxR1 is not only easily inhibited by electrophilic 
compounds, but may also be converted into its pro-oxidant SecTRAP form, whereby it 
further promotes accumulation of ROS as a means of inducing cancer cell death. Over 
the years evidence is increasingly accumulating that links TrxR1 targeting to cancer 
cell death and thus strengthens this approach187, 189, 196, 224-226. 
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4 Thiols in redox regulation 
 
ROS may modify histidine, tryptophan, tyrosine, and methionine in addition to cysteine 
residues. Tryptophan, histidine and tyrosine oxidation is, however, less favored and 
considered to be irrelevant for normal physiological processes227, 228. Methionine 
oxidation is physiologically observed and can be reversed via methionine sulfoxide 
reductases122. This process is usually considered a repair mechanism and its 
contribution to redox signaling is thus not fully established yet. So far all evidence 
suggest that cysteine residues are the prime residues involved in redox signaling. It is 
important to mention though that most of the evidence is obtained from individual 
studies of known thiol proteins. The sulfenic acid oxidation for example is unstable in 
most proteins and thus difficult to observe. Current research puts therefore a lot of 
effort into the development of methods to monitor, identify and analyze redox sensitive 
cysteine residues229.  
 
4.1 Cysteine & selenocysteine as targets for oxidative 
modifications 
 
Cysteine 
 
Cysteine is a polar, sulfur containing amino acid that is characterized by its mildly 
acidic thiol side chain (RSH). It is among the least abundant amino acids, but often 
directly involved in catalysis, protein binding, stabilization and other functions. Its 
general biochemical properties are difficult to characterize as they are highly influenced 
by the local environment. Exposed cysteine residues in low molecular weight thiols, 
like GSH, have typically pKa values around 8-9, whereas the pKa in thiol-proteins can 
be as low as 3.5 due to a suitable microenvironment18, 230.  
 
A low pKa is considered a key property for oxidative reactivity as it promotes the 
formation of the more reactive deprotonated thiolate (RS-) at physiologic pH229. This 
dependence is illustrated by H2O2 mediated oxidation of low molecular weight thiols 
that requires the thiolate anion87. However, several observations clearly show that this 
is not the sole determinant of oxidative susceptibility. A common example is the 
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comparison of the protein tyrosine phosphatase PTP1B and peroxiredoxin 2. Both have 
a similar pKa, whereas the reaction rate constant of Prx2 with H2O2 is a million times 
higher than for PTP1B231, 232. This feature was recently attributed to the additional 
activation of the peroxide substrate via a unique and conserved hydrogen bonding 
network that is formed by the amino acids (Pro, Thr, Arg and either His, Glu or Gln)232, 
233. Noteworthy, the ability of sulfur to adopt a wide range of oxidation states (-2 to +6) 
is based on its electron configuration and available d-orbitals, thus enabling a number 
of different modifications234 (Fig. 9).    
 
Selenocysteine 
 
Selenocysteine (Sec; U in one letter code) is a reactive analogue of cysteine. It is 
considered the 21st naturally occurring amino acid235 and distinguished by a selenium 
containing selenol group in place of the sulfur containing thiol group (Fig. 8). It has 
unique biochemical properties such as a high nucleophilicity and a low pKa of 5.3. The 
selenol group is thus several magnitudes more acidic and reactive in redox reactions 
compared to its thiol counterpart236, 237. This characteristic was shown for the 
selenoproteins GPx and TrxR1. The reactivity of both was drastically reduced as the 
Sec residue was replaced by Cys238, 239.  
 
Figure 8. Comparison of cysteine and selenocysteine. 
 
However, this does not imply that selenoproteins have a higher capacity to regulate 
redox processes in general. The thiol protein Prx2, for example, has a similar reaction 
rate as the selenoprotein GPx when catalyzing the decomposition of H2O2232. Another 
example is the non-selenium TrxR variant of Drosophila melanogaster. The wild type 
variant, having an -SCCS- active site, showed a similar catalytic activity as when 
mutated to the mammalian -GCUG- motif173.  
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All in all, the presence of a Sec residue does not reflect a higher activity per se. Other 
parameters, as for example the microenvironment of the active site and the substrate, 
are likely contributing to the kinetics and need thus to be considered as well173, 229. 
Some kind of advantage can nevertheless be expected by Sec over Cys, particularly 
since the cells have developed a specific machinery for selenoprotein production that is 
considered “costly and inefficient”173. Potential advantages might include a greater 
flexibility towards substrates, efficient support for one-electron-transfer reactions, its 
high nucleophilicity that leads to fast reaction rates with electrophiles or its resistance 
to inhibition via overoxidation173, 240-243. Interestingly it was also shown that Sec can be 
substituted by Cys in TrxR1 either in vivo under selenium deficient conditions244, 245 or 
when cells were treated with thiophosphate thus showing that the less reactive variant 
can potentially serve as backup197, 245.  
 
4.2 Relevant thiol modifications  
 
As mentioned above, cysteine residues whose side chains are deprotonated at 
physiological pH, are prime targets for reversible oxidative modifications that regulate 
their function and thus important pathways. A number of physiologically relevant 
modifications include disulfide bonds (RS-SR'), sulfenic acid (SOH), sulfinic acid 
(SO2H), sulfonic acid (SO3H), S-glutathionylation (RS-SG), S-nitrosylation (RSNO) 
and sulfhydration (RSSH) as summarized in Figure 9. They each have distinct 
chemical properties, functions and formation pathways. 
 
Sulfenic acid is the first oxidation state that is induced by H2O2 exposure. It is unstable, 
reactive, short lived and thus difficult to monitor246. Due to its unique chemical 
properties it is recognized as a critical intermediate in redox signaling – it can be either 
oxidized further or directly reduced back to a thiol234. The most common subsequent 
modification is the formation of inter- and intramolecular disulfide bonds, which have 
been shown to affect enzyme activity, subcellular localization and protein-protein 
interactions234, 247. Disulfide bonds are relatively stable and typically cleaved via thiol-
disulfide exchange reactions with enzymes such as Trx or Grx. A high and prolonged 
exposure to H2O2 on the other hand, promotes oxidation to the point of forming the 
essentially irreversible sulfinic and sulfonic acids248, 249. This cysteine overoxidation is 
typically correlated to oxidative stress and can be prevented by other reversible cysteine 
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modifications such as GSH/GSSG mediated S-glutathionylation250 (Fig. 9). An 
example is PTP1B were S-glutathionylation was shown to display a regulatory role by 
preventing complete inhibition251. In addition to its protective role it is also involved in 
the modulation of enzyme activity, protein-protein interaction and transcription factor 
regulation250, 252, 253.       
Figure 9. Overview of relevant oxidative thiol modifications. The blue highlighted variants 
refer to a number of reversible modifications that are important in redox signaling. Oxidizing 
molecules are highlighted. Removal of the modifications is facilitated by the Trx and GSH systems 
respectively. Sulfinic and sulfonic acid, highlighted in red, occur in the presence of elevated H2O2 
levels and are often seen as markers of oxidative stress. However, it has been shown that 
sulfiredoxin is able to reduce sulfinic acid back to sulfenic acid in a subset of peroxiredoxins123. 
This figure was modified from Chung et al. 2013254.   
 
Two more reversible cysteine modifications include S-nitrosylation146, 255-257 and 
sulfhydration40. The later was for example shown to modulate PTP1B activity as a key 
aspect of the ER stress response258. In general, the study of physiological relevant 
sulfhydration is at the very beginning and thus the understanding still very limited. S-
nitrosylation on the other hand as already been implied to be an important regulator of 
numerous thiol-proteins and their signaling pathways259. For more information on S-
nitrosylation see chapter 2.2 “reactive nitrogen species”. 
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4.3 Principle mechanisms in redox signaling 
 
There are three principle concepts described by which redox signaling may be 
mediated8:  
 
The thermodynamic concept 
 
The thermodynamic principle implies that all couples of oxidized and reduced thiols are 
in an equilibrium, which is determined by the cellular redox potential260. The 
thiol/disulfide ratio of the main redox buffer glutathione261 ([GSH]2:GSSG), is thus 
used to correlate redox signaling processes to the cellular redox potential as a whole. A 
change in the [GSH]2:GSSG ratio as response to oxidizing or reducing conditions is 
thought to affect the thiol/disulfide ratios of other proteins depending on their redox 
potential and therewith their function260, 262. However, the concept of the [GSH]2:GSSG 
ratio being the actual cause of a response and therewith a central mediator of redox 
signaling as well as the usefulness of thermodynamic and electrochemical  parameters 
in redox signaling in general is increasingly questioned263. Catalyzed reactions by 
enzymes like Trx or Grx are far superior in terms of kinetics than the slow direct thiol-
disulfide exchange reactions and thus better suitable to regulate dynamic redox 
signaling processes127, 264. Nonetheless might the [GSH]2:GSSG ratio have an indirect 
functional influence on redox signaling processes. A change in the ratio may affect 
protein S-glutathionylation as a whole and thus H2O2 mediated signaling.    
 
Direct oxidation of sensitive thiol proteins 
 
This concept favors, in contrast to the thermodynamic model, a more specific cellular 
response. As discussed before, thiols are differently susceptible towards oxidative 
modifications with only a few being sensitive enough to participate in redox events. An 
oxidative signal, as for example a burst of H2O2, could thus transiently oxidize some of 
these thiol proteins in order to activate or deactivate them as a principle of signal 
transmission. The activation of various pathways and the strength of the response could 
be regulated via the levels of the oxidants, compartmentalization of the oxidative signal 
or the deactivation of the reducing and oxidant scavenging enzymes.  
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However, according to kinetic modeling are Prxs the only known cellular thiol proteins 
that are sufficiently abundant and reactive towards H2O2265. Direct oxidation of other 
thiols should thus not be relevant in their presence. A potential solution is the 
“floodgate” hypothesis that suggests local H2O2 signaling as a consequence of Prx 
inhibition via overoxidation, which could be observed in H2O2 exposed cells266-268. 
However, this is argued by recent studies showing that relevant H2O2 concentrations for 
Prx overoxidation are not reached during signaling269, 270.   Instead it was demonstrated 
that Prx1 is locally inhibited via transient phosphorylation by activated Src family 
kinases in response to growth factor stimulation39, 269. Two other kinases that also 
regulate Prx1 activity via phosphorylation in response to H2O2 are the tumor 
suppressors Mst1 and Mst2271. Nonetheless, this may not entirely explain the frequently 
observed oxidation of phosphatases such as PTPs and PTEN215, 231, 272-277. They are only 
mildly reactive and would require high H2O2 concentrations to be sufficiently oxidized 
during fast signaling events.  
 
Most data emanate from in vitro models and might thus not always reflect the in vivo 
situation were numerous additional parameters potentially contribute to the process. For 
example, the reactivity may be affected by posttranslational modifications as in case of 
the just mentioned phosphorylation of Prx1. Another example is given by caspase-3, 
which was shown to react 40 times faster with H2O2 in the presence of its substrate278. 
Yet another example is related to conformational changes of the Src kinase. Normally it 
exhibits a closed inactivated confirmation that is insensitive to H2O2. In response to 
growth factor cytokine stimulation it is, dephosphorylated whereby it acquires an open 
confirmation. In this state it exhibits redox sensitive cysteine residues that further 
stimulate the activity if oxidized and also prevent the kinase from getting inactivated279.   
 
Sensor protein mediated oxidation 
 
A solution to the aforementioned direct oxidation of thiol proteins is a third model that 
proposes regulated oxidation of target proteins via thiol exchange reactions with 
specific sensor proteins of which peroxidases are suggested to be the best candidates39. 
An example is given by the yeast transcription factor Yap1 that is oxidized via the 
glutathione peroxidase-like protein GPx3280 and the thioredoxin peroxidase Tsa1281. In 
principle, the sulfenic acid of the oxidized peroxidase forms an interdisulfide bond with 
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Yap1. The subsequent exchange with a second cysteine in Yap1 generates in turn an 
intramolecular disulfide and recycles GPx3 or Tsa1. An example in mammals involves 
the transfer of the oxidation state of Prx4 to PDI, which in turn promotes the disulfide 
formation in its target protein116. Nonetheless, further studies are clearly needed to 
show the physiological relevance of these processes. A particularly interesting 
possibility in this context is the Prx mediated oxidation of PTPs, which is often 
discussed, but has not been shown yet.  
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5 Redox sensitive transcription factors 
 
Gene transcription is regulated by the effects of the chromatin structure and the 
interactions of transcription factors, which are regulatory proteins that bind to specific 
DNA sequences in order to mediate rapid transcriptional responses. The specific 
actions of these factors are regulated by an exceedingly complex network of protein-
protein interactions and post translational modifications such de-/phosphorylation and 
redox modifications. All of these processes occur on several levels: i) regulation of 
transcription, mRNA stability and translation; ii) stability and prevention of 
degradation; iii) cytoplasm-nuclear transport; iv) DNA binding and nuclear 
transactivation of the transcription factor as well as v) regulation of co-activators and 
repressors282, 283. 
 
The precise mechanisms of redox regulated gene transcription are still rather poorly 
characterized. It was only in coherence with the growing acceptance that oxidants act as 
mediators and modulators of signaling pathways and protein function that these aspects 
received attention. A notable finding in the earlier days was the direct correlation 
between NFB activity and oxidative molecules, making it the first mammalian 
transcription factor shown to be redox regulated282, 284, 285.  
      
Several additional transcription factors such as AP-1, Nrf2, HIF and p53 have since 
then been shown to be either directly or indirectly regulated by redox processes that are 
primarily mediated by the Trx and GSH systems283. Interestingly, many of these 
transcription factors are closely linked to cell survival and cell development due to their 
importance in stress response, proliferation, differentiation as well as apoptosis. Their 
deregulation is thus often the basis of various pathophysiological conditions, which 
further highlights the importance of studying the underlying regulatory mechanisms282, 
283.  
 
Moreover, various pathways that regulate the activation of transcription factors may be 
functionally intertwined. For instance, Nrf2 activation that is typically mediated by 
oxidative stress or via reactive electrophiles, promotes the transactivation of antioxidant 
and detoxifying enzymes, including components of the Trx and GSH systems. 
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Upregulation of these systems affects in turn oxidant levels and redox sensitive 
processes such phosphorylation mediated signaling cascades, which is for instance 
highlighted in the H2O2 supported activation of NFκB286-288. The interested reader is 
referred to the recent reviews by Brigelius-Flohé, R. and Flohé, L.282 as well as 
Marinho, H. et al.283 for further details on the overall concepts of redox regulation in 
gene transcription.  
The following chapters will briefly introduce the basic concepts of NFB, HIF and 
Nrf2 regulation in reference to Paper III.  
 
NFκB                   
 
NFB (nuclear factor kappa-light-chain-enhancer of activated B cells) refers to a 
family of dimeric transcription factors that consist of the p65 (RelA), RelB, c-Rel, p50 
and p52 subunits, with the last two being produced from their precursors p105 and 
p100289. All of these proteins have a N-terminal Rel homology domain (RHD) that 
contains a nuclear localization signal (NLS) and that is also responsible for DNA and 
protein binding. However, only the three Rel subfamily proteins contain additional C-
terminal transactivation domains (TADs)289. Homodimers of the p50 and p52 proteins 
are thus often discussed as repressors as they can bind to the DNA, but are unable to 
activate transcription290. 
 
The NFB system can be found in almost all cells and is primarily involved in the 
immune and inflammatory response as well as in cellular growth and apoptosis. It is 
typical activated by cytokines (e.g. IL-1, TNFα), bacterial and viral antigens (e.g. LPS, 
PAMPs) or growth factors (e.g. EGF) that initiate a response by stimulating different 
receptor families (e.g. RTK, TLR, TNFR) that in turn activate NFB through distinct 
phosphorylation cascades282. The list of NFB targets encompasses several hundred 
genes including cytokines/chemokines, growth factors, adhesion molecules, receptors, 
stress response genes, regulators of apoptosis, enzymes and many more. The incorrect 
regulation of NFB is furthermore associated with many diseases such as muscular 
dystrophy, cancer, diabetes and atherosclerosis291. An extensive summary of most 
aspects regarding NFB, including extensive lists of activators and related diseases, can 
be found on the web-page of the “The Gilmore Lab” (http://www.bu.edu/nf-kb/) (Fig. 
10).   
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NFB belongs to the type of transcription factor that is present in the cytosol in an 
inactivated state. Upon stimulation NFB is released from its inhibitor IB and 
translocates into the nucleus where it binds to specific promoter regions of its target 
genes together with the transcriptional coactivators CBP and p300. This setup enables a 
rapid initial responds to harmful stimuli as is does not require new protein synthesis 
(Fig. 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Typical activation pathway for 
NFB. See text for further details. The 
predominant cytosolic NFB complex is 
considered to be p50/p65/IBα. Activation is 
initiated by receptor mediated 
phosphorylation cascades in response to 
stimulation. The central event is IB 
phosphorylation via IKK, whereupon IB is 
ubiquitinated and degraded. The p65/p50 
dimer translocates to the nucleus and binds 
to specific sequences within the promoter 
regions. The coactivators CBP and p300 are 
also recruited and gene transcription is 
initiated. NFB activity is modulated by the 
Trx and GSH systems in several ways as 
indicated. The here depicted scheme is only 
one of several pathways. Especially the 
initiating phosphorylation cascades and the 
specific response to certain stimulations is 
complex292. This figure was modified 
from282.  
 
In the absence of stimulation, NFB dimers are sequestered in the cytosol by members 
of the IB family (Inhibitors of B) such as IBα (major variant), IB, IB, IB 
and BCL-3293. These proteins contain several ankyrin repeats that mediate binding to 
the RHD, which in turn prevents NFB from binding to the DNA and from 
translocating into the nucleus by interfering with the NLS. The key event in NFB 
activation is thus the release of the NFB dimer from the cytosolic complex288. This is 
achieved by signal-induced phosphorylation of IB, which leads to ubiquitination and 
subsequent proteasomal degradation of the inhibitor294. IB phosphorylation is 
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primarily catalyzed by the IB kinase (IKK) – a complex that is composed of IKKα, 
IKK and two IKK subunits that form the NFB essential modulator (NEMO)295 (Fig. 
10). Notably, the upstream events leading to NFB activation as depicted in Figure 10 
are complex and depend amongst other things on the receptor involved.  
 
As mentioned above, NFB is the first transcription factor that has been shown to be 
redox regulated. In contrast to early ideas, which implied that H2O2 could directly 
initiate NFB activation, are current concepts promoting the view that H2O2 rather 
supports the activation by other stimuli287, 288. The earlier notion that H2O2 directly 
activates NFB is thought to have come from the overlapping effects of NOX 
activators and NFB enhancers282, 286. 
 
The beneficial effect of oxidants on NFB activation has been mainly attributed to the 
modulation of redox sensitive de-/phosphorylation events296. Oxidative inactivation of 
phosphatases for example, leads to increased phosphorylation states within all levels of 
the NFB activation cascades and thus enhanced signaling297. The diminishing effects 
on NFB activation by Trx overexpression are therewith suggested to involve the 
reactivation of phosphatases and the antioxidant properties of the system286, 298. 
Interestingly, nuclear Trx1 is, in contrast to its preventive role in the cytosol, essential 
for DNA binding of the p65/p50 complex by catalyzing the reduction of the critical 
Cys62 in the p50 subunit151, 299. Another regulatory mechanism of the Trx system is 
given by TRP14, which has been implied in the prevention of NFB activation by 
keeping the dynein light chain LC8 reduced. Reduced LC8 binds IB and prevents IKK 
mediated phosphorylation and subsequent degradation300. Furthermore, the Grx system 
has been implied to modulate NFB activation via deglutathionylation of kinases and 
phosphatases. It was also shown that Grx mediated deglutathionylation of critical 
cysteines in the p65 and p50 subunits possess a regulatory mechanism301, 302. 
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HIF 
 
Hypoxia inducible factors (HIFs) are transcription factors that mediate the response to 
changes in oxygen tension during physiological and pathological conditions such as 
cancer or cardiovascular disease at systemic and cellular levels. Their activation has 
thus been implicated in angiogenesis, erythropoiesis and glycolysis303. 
 
HIFs are dimeric proteins composed of the constitutive HIF-1 subunit and one of the 
three inducible HIFα proteins (HIF-1α, HIF-2α, HIF-3α), with HIF-1α being the most 
extensively studied form. HIF-1 is present in excess so that the HIF-1α levels 
determine the overall transcriptional activity304.  
 
All HIF-1α proteins contain an oxygen-dependent degradation domain that has two 
conserved proline residues. At normal oxygen levels, at least one is hydroxylated by 
prolyl hydroxylases (PHDs). The hydroxylated protein is recognized by the Hippel-
Lindau tumor suppressor protein (pVHL), which recruits an ubiquitin ligase that targets 
HIF-1α for subsequent proteasomal degradation305. The catalytic activity of the PHDs 
is oxygen dependent and thus inhibited at low oxygen tension, enabling HIF-1α 
stabilization and transcriptional activation306. Notably, HIF-1α can also be hydroxylated 
at an asparaginyl residue in an oxygen dependent manner by the factor inhibiting HIF 
(FIH). This modification blocks association with the p300 coactivator and represses 
thus HIF dependent transactivation307, 308.    
 
The finally stabilized HIF-1α dimerizes with HIF-1 and binds to the specific hypoxia 
response elements (HRE) that are characterized by the (G/ACGTG) motif in the 
promoter region of its target genes to initiate transactivation309. FIH mediated 
hydroxylation is also inactivated under hypoxic conditions allowing thus recruitment of 
the CBP/p300 coactivators310 (Fig. 11).  
 
Although HIF activation is predominantly mediated by low oxygen levels it has been 
shown that additional, hypoxia-independent, mechanisms activate this transcription 
factor as well. For instance, HIF activation in normoxia was observed upon stimulation 
with growth factors, cytokines or hormones311. The underlying mechanism is suggested 
to be a combination of NOX mediated H2O2 production and NFB activation312, which 
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promotes HIF-1α transcription based upon a NFB-binding site in the HIF-1α promoter 
region313, 314. Other studies also showed that lipopolysaccharide stimulates HIF-2α 
signaling via NFB activation, thus further linking these transcription factors. The 
connection between these two pathways is also often discusses in cross-tolerance as for 
example an inflammatory stimulus may protect an organ from an subsequent ischemic 
insult315.  
 
The remaining question is how HIF-1α stabilization is achieved under normoxic 
conditions. HIF-1α has been reported to be redox sensitive, but as to how this affects its 
stabilization is not known yet. Instead it is suggested that H2O2 oxidizes the catalytic 
Fe2+ in PHD to Fe3+ thus inactivating the enzyme316. For instance, H2O2 production due 
to glucose oxidase in the cell culture medium was shown to promote HIF-1α 
stabilization by inhibiting hydroxylation317. Other HIF-1α stabilizing examples include 
NOX1 overexpression, mitochondria-derived ROS or the aforementioned H2O2 
production during NFB activation64, 65, 318. HIF, like many other transcription factors, 
is furthermore regulated by H2O2 via effects on redox sensitive proteins within the 
translation and proteasomal degradation machineries283 (Fig. 11). 
 
 
Figure 11. Principle 
regulation of HIF. See text 
for further details. HIF-1α 
and HIF-1β are the 
predominant and most 
studied variants. HIF-1α is 
hydroxylated by PHD, which 
marks the protein for 
subsequent ubiquitination 
and degradation under 
normal conditions. The 
catalytic function of PHD is 
oxygen dependent and thus 
inhibited in hypoxia. 
Furthermore, PHD is inhibited by ROS, thus enabling HIF activation also in normoxia. PHD inhibition 
results in the translocation of HIF-1α into the nucleus where it dimerizes with HIF-1β. The complex binds to 
specific HRE sequences within the promoter region of target genes and thus activates transcription. The 
role of the Trx system in the regulation of HIF is yet largely unclear. However, a number have been 
proposed as indicated. 
 
 
Despite the case that reactive oxygen species are able to promote HIF-1α stabilization 
did neither TrxR1 overexpression nor depletion display a notable effect on HIF 
stabilization or function319, 320. This lack of effect can potentially be attributed to a 
number of reasons: i) the presence of the GSH system, which effectively controls 
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reactive oxygen levels in the cytosol; ii) residual TrxR1 levels in knockdown cells may 
be sufficient for Trx1 reduction; iii) back-up systems for Trx1 reduction321, 322 or that 
iv) catalytic mechanisms are not that essential. 
 
Interestingly however, numerous studies proposed that redox active Trx1 may modulate 
stabilization, translation, translocation into the nucleus as well as DNA binding and 
transactivation of HIF-1α320, 323-329. For instance, it is assumed that the Trx1 (or via Ref-
1) catalyzed reduction of cysteine 800 in HIF-1α is required for CBP/p300 recruitment 
and thus transactivation323, 325 (Fig. 11). Furthermore did Kim et al. propose that Trx1 
promotes nuclear localization and prevents degradation of HIF-1α by promoting the 
dissociation of pVHL and HIF-1α, as shown via Trx1 knockdown and overexpression 
experiments326. These results are well in line with several other studies showing that 
Trx1 overexpression markedly enhanced HIF-1α protein levels and target gene 
expression (e.g. VEGF, COX-2) under hypoxic and partly also normoxic conditions324, 
326, 327, 329. Welsh et al. furthermore pointed out that this effect did not account for 
changes in mRNA levels324, which was later confirmed by Zhou et al., who additionally 
demonstrated that Trx1 overexpression promotes cap-dependent translation of HIF-1α 
by activating p70S6K and eIF-4E329. Activation of these components is essential for 
translation initiation and was furthermore shown to be mediated by the PI3K/Akt and 
MAPK signaling pathways. The exact mechanism is not known, but it was proposed 
that Trx1 mediates activation of these pathways by binding to and thus inhibiting 
PTEN, which is a negative regulator of these signaling pathways159, 329, 330 (Fig. 11). In 
addition there are several studies that further illustrate the connection between “Trx1 – 
PI3K/Akt/MAPK – HIF activation” or more general “PI3K/Akt/MAPK – HIF 
activation” in a number of conditions331, 332.  These results are furthermore in agreement 
with the aforementioned studies that reported HIF-1α stabilization and activation to be 
largely independent of TrxR1 as PTEN inhibition is facilitated via protein-protein 
binding. 
 
One aspect that is still debated is whether Trx1 is essential for HIF-1 activation or 
whether the reported mechanisms can only be attributed to elevated Trx1 levels. 
Naranjo-Suarez et al. showed recently that Trx1 is neither essential for HIF-1α 
stabilization nor its activity320. These results are however, in stark contrast to other 
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studies showing that Trx1 knockdown, expression of a redox inactive variant or 
inhibitors could markedly decrease HIF activation324, 326, 328, 333.  
 
Nrf2 
 
Nrf2 (Nuclear factor (erythroid-derived 2)-like 2) is one of the most important 
transcription factors in regulating detoxification and oxidative stress response. 
Activation is typically mediated by a variety of exogenous and endogenous stressors 
such as electrophilic agents and reactive oxygen species334. It binds to a common DNA 
regulatory element called the antioxidant responsive element (ARE; alternatively called 
EpRE for electrophile responsive element) in the promoter region of genes that 
collectively promote cell survival such as detoxifying enzymes, antioxidant proteins 
(Trx, TrxR, Prx1, GPx2), enzymes for glutathione synthesis (-glutamyl-cysteine 
synthetase), receptors, transcription factors, proteases and many more111, 131, 282, 335, 336. 
 
Nrf2 is bound to its inhibitor Keap1 under normal conditions, which targets Nrf2 
constantly for proteasomal degradation. Keap1 is also acting as sensor for Nrf2 
activating compounds causing it to undergo a conformational change by either binding 
to or oxidizing critical cysteine residues337, 338. As a consequence, the Nrf2-Keap1 
binding is partly disrupted so that Nrf2 ubiquitination and degradation is blocked. Nrf2 
is however not released, but instead occupies the now inactive Keap1 so that newly 
synthesised Nrf2 can freely translocate into the nucleus where it forms heterodimers 
with bZIP transcription factors such as Mafs (predominantly), c-Jun or ATF4 prior 
binding to ARE339 (Fig. 12). It has been, and still is, debated whether Nrf2 also 
dissociates from Keap1282. However, a recent study showed clearly that Nrf2 is indeed 
not released from Keap1340. In agreement with this it was also demonstrated that Nrf2 
activation is strongly affected by H2O2 on the translational level. Steady state 
concentrations of 12.5 M promote Nrf2 synthesis with a rate that exceeds nuclear 
translocation, which furthermore suggests that there has to be a very potent, but yet 
unknown H2O2 sensor283, 341.    
 
Keap1 is a homodimer that functions as adaptor of the Cullin-3-based E3 ligase. Each 
Keap1 subunit contains furthermore 27 cysteine residues of which 9 have been 
predicted to be reactive due to a basic microenvironment342. Based on the broad 
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chemical heterogeneity of Nrf2 activators it is also suggested that these are targeted 
differently by different electrophiles, which may furthermore translate into specific 
cellular responses343. Cys151, Cys273 and Cys288 are crucial examples among these 
residues. Cys151 was for instance shown to be important for H2O2 mediated Nrf2 
activation by forming an intermolecular disulfide with Cys151 of the second Keap1 
molecule, which releases Cullin-3 that is required for degradation and Keap1 
dimerization344, 345. The Cys273 and Cys288 residues are furthermore Zn-correlated and 
essential for the response to many Nrf2 activators. A modification of those disrupts the 
Zn-stabilised conformation of Keap1 and thus inhibits degradation346 (Fig. 12).  
 
Figure 12. Principle regulation of Nrf2. 
See text for further details. Nrf2 is bound 
to its inhibitor Keap1, which targets it for 
proteasomal degradation. Keap1 also 
serves as redox sensor and changes 
conformation in response to oxidation or 
alkylation of its crucial cysteines. The 
complex is thus stabilized and degradation 
prevented. Newly synthesized Nrf2 
bypasses the loaded Keap1 and is 
translocated into the nucleus where it 
binds to specific ARE sequences. Nuclear 
Trx1 is important for the reduction of 
critical cysteines in Nrf2. One is important 
for DNA binding, whereas the other is 
involved in nuclear export. Nrf2 is 
additionally subject to phosphorylation, 
which further modulates its activation. 
Among the Nrf2 target genes are enzymes 
of the Trx & GSH system. The 
upregulation of these counters the initial 
Nrf2 activating conditions and facilitates 
detoxification and antioxidant defense. 
This figure was modified from282.  
 
Not only Keap1, but also Nrf2 itself is subject to redox regulation. It contains at least 
two redox sensitive cysteine residues within its nuclear localization signal (NLS) and 
nuclear export signal (NES) sequences. Oxidation of Cys183 in the NES site interferes 
with Crm1 (chromosome region maintenance 1; exportin) binding and thus retains Nrf2 
in the nucleus347, 348. A similar effect was also reported for nuclear Keap1, which thus 
further prevents the nuclear export of Nrf2349. These oxidations may be reversed by the 
GSH or Trx systems. Trx1 was for example shown to promote nuclear export of 
Nrf2158. This particular function is highlighted in txnrd1-/- cells that showed a prolonged 
Nrf2 transactivation that was attributed to Nrf2 persistence in the nucleus350. Reduction 
of Cys506 in the NLS region that is catalyzed by Trx1/Ref-1152, 158 is furthermore also 
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important for the interaction with the coactivators CBP/p300 as well as for DNA 
binding351 (Fig. 12).  
  
Nrf2 is additionally regulated by phosphorylation – certain events promote Nrf2 
activation, whereas it is diminished by others. The Ser40 residue is for example 
phosphorylated by the redox sensitive protein kinase C (PKC), which prevents binding 
to Keap1 and promotes nuclear translocation352. On the other hand, Nrf2 can be 
phosphorylated by Fyn at Tyr568 in the nucleus, promoting Crm1 interaction and thus 
nuclear export. Activation and nuclear translocation of Fyn is seen several hours after 
Nrf2 activation and regulated by a H2O2 activated phosphorylation cascade353 (Fig. 12). 
Processes that involve phosphatases and kinases are furthermore susceptible to cross-
talk between different signaling pathways – an aspect that has been compiled by 
Brigelius-Flohé R. and Flohé L. in the context of Nrf2282, 354.   
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6 Projects 
 
6.1 Aims 
 
The thioredoxin system has been discussed in a variety of different contexts and many 
of its important roles in health and disease have been discovered. However, its 
involvement in cellular pathways is versatile and countless aspects that contribute to the 
final outcome of the cell are still unknown. With this in mind we studied three separate 
aspects of the Trx system that had the following specific aims: 
 
Paper I  
 
 TrxR1 targeting and inhibition by Pt, Au and Pd based compounds in relation to 
cancer cell survival. 
 Characterizing the mechanism of inhibition and the potential formation of 
SecTRAPs in vitro and in cell culture. 
 
Paper II 
 
 Analyzing the underlying mechanism of the intracellular localization pattern of 
the v3 splice variant of TrxR1. 
 Clarifying whether the effects on actin polymerization can be attributed to a 
potential redox activity of the Grx-domain of v3 or whether other properties are 
essential. 
 
Paper III 
 
 Developing a method to simultaneously study the behavior of several 
functionally intertwined transcription factors with single cell resolution.  
 Applying this method to study the regulation of Nrf2, HIF and NFκB, which 
are all in part regulated by the Trx system.  
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6.2 Paper I 
 
Noble metal targeting of thioredoxin reductase – covalent complexes with 
thioredoxin and thioredoxin-related protein of 14 kDa triggered by 
cisplatin.  
Stefanie Prast-Nielsen*, Marcus Cebula*, Irina Pader, Elias S. J. Arnér. Free Radic Biol Med. 2010; 49: 
1765-1778. *Equal contribution 
 
 
Figure 13. Summary of Paper I. See text for a detailed description. a, b) The inhibition profile 
is dependent on the elemental properties of the metal and the choice of ligand. Cellular uptake 
and inhibition is particular affected. c, d) The various salts are preferentially targeting the Sec 
residue of TrxR1 and potentially converting the enzyme to its pro-oxidant SecTRAP form. e) 
Cisplatin and auranofin could also both modify the enzyme into its potentially Sec-TRAP form 
within cells. f) Cisplatin has additional features with regard to TrxR1 as it cross-links Trx1 and 
TRP14 to its subunits. 
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Results 
 
Elemental properties of the metal and choice of ligands are the major parameters 
effecting uptake and TrxR1 inhibition   
 
Pd based compounds have already been synthesized and validated in terms of 
anticancer effectiveness and cytotoxicity in comparison to Pt based drugs on account of 
their chemical similarity355-358. In line with these studies we demonstrated that Pd as 
well as Au based salts were exceedingly more potent than their Pt counterparts in terms 
of inhibiting TrxR1 in vitro as well as in cell extracts (Fig. 13a). The ligand 
substituents on the other hand affected the inhibition rates only marginally - KAuCl4 
for example, performed similar to auranofin as the Pt salts did compared to cisplatin. 
This pattern was in contrast to the cellular inhibition profile where cisplatin and 
auranofin both inhibited TrxR1 several fold more efficiently than their KAuCl4 and 
K2PtCl4 counterparts. Particularly, the comparable Pd salt K2PdCl4 had surprisingly 
mild effects given that it was an efficient inhibitor in crude cell extract (Fig. 13b). This 
rather indicates a limited cellular uptake than extensive off target binding.   
 
Furthermore, the inhibition of TrxR1 correlated well with a reduction in cell viability, 
suggesting that the disruption of the thioredoxin system might to some extent contribute 
to the cytotoxic profile of the respective compounds. Off target effects can however, 
not entirely be excluded due to the electrophilic nature of the compounds as indicated 
for instance by KAuCl4, that not only inhibited TrxR1, but also Trx1 in cell culture. 
  
In vitro characterization of SecTRAP formation  
 
In context of intracellular TrxR1 targeting it is furthermore important to study the 
specific mechanism of inhibition, i.e. whether the complete enzyme activity is inhibited 
or whether “only” the Sec-dependent functions are impaired by which the enzyme may 
transform into its pro-oxidant SecTRAP form. The gain of function in this case would 
likely support the anti-cancer efficiency compared to a mere decrease in cellular TrxR1 
activity, which was shown to exhibit rather mild effects in a number of cases196, 359 
(Fig. 13c). 
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Using recombinant TrxR1 we noted that the inhibition profile was strongly suggestive 
of preferential binding to the highly nucleophilic selenolate anion in the C-terminal 
active site. The evidence for this mode of action includes: I) NADPH dependent 
reduction of the selenosulfide prior incubation with the compounds was needed for 
inhibition; II) approximate reaction order of 1 (stoichiometric ratio between metal 
compound and enzyme); III) diminished DNTB (Sec-dependent), but sustained juglone 
(Sec-independent) reduction and thus NADPH oxidase activity; IV) no inhibitory effect 
on the structurally related glutathione reductase as well as V) fast inhibition kinetics 
that are in agreement with preferential targeting of the highly reactive and accessible 
selenolate. Although the direct binding to the selenolate was not explicitly proven in 
this study it shall be noted that the susceptibility of a Sec-residue towards electrophilic 
compounds was reported by others131, 186, 360-362, including a study showing direct 
derivatization of the Sec-residue in TrxR1 by platinum compounds via X-ray 
crystallography363 (Fig. 13d).  
 
Identification of intracellular SecTRAP formation as proof of principle  
 
In order to test if such TrxR1 derivatives can be formed intracellularly we performed 
immunoprecipitation studies on cell extracts of cisplatin and auranofin treated cancer 
cells followed by activity measurements as a proof of principle. In agreement with the 
SecTRAP concept we found that the ability to redox cycle with juglone (Sec-
independent) was maintained to a larger extend than the capacity to reduce Trx1 (Sec-
dependent). When extrapolated to the cell extract we estimated that cisplatin could 
derivatize up to 40% of the enzyme, whereas auranofin treatment led foremost to a 
strong decrease in overall TrxR1 activity with only up to 20% derivatized enzyme (Fig. 
13e). However, the yield and the recovery of the enzyme was probably not qualitatively 
and the whole handling procedure may have further altered the activity of the enzyme 
as well. A solid conclusion regarding the intracellularly formed SecTRAPs is thus 
difficult, but we believe that this data further support the pro-oxidant concept of 
derivatized TrxR1 enzymes.   
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TrxR1:Trx1 and TrxR1:TRP14 complex formation and potential functions 
 
Surprisingly, we also discovered the intracellular formation of covalently linked 
complexes of TrxR1 with either Trx1 or TRP14 upon treatment of cells with cisplatin, 
and to some extent with the Pt salt, but not with any of the Au and Pd compounds (Fig. 
13f). A potential function or contribution of these complexes to cisplatin mediated 
cytotoxicity and anticancer efficacy is not established yet. Considering the two 
observations that Trx1 activity was not inhibited by cisplatin and that only a minor 
fraction of the protein was actually trapped in the complex suggests that inactivation of 
Trx1 is not part of a potential mechanism. On the other hand, the trapping involved 
rather high amounts of TRP14 compared to their basal levels, indicating that disruption 
of TRP14 dependent functions could be an important consequence.   
 
While analyzing tryptic digests of the complex via mass spectrometry we could not 
identify the nature of the cross-link. With the exception of the C-terminal active site in 
TrxR1 we detected however, all other respective active sites, which were also 
essentially unmodified. Cisplatin might thus not link both enzymes via their active sites 
despite its known ability to cross-link nucleotides and proteins. Potential alternative 
mechanisms might involve cisplatin mediated cross-linking at the interface between the 
enzymes or conformational changes due to intraprotein cross-linking. Another 
possibility is cross-linking via surface exposed residues that have undergone oxidative 
modifications. These modifications may be mediated by potentially high local ROS 
concentrations due to the NADPH oxidase activity of the cisplatin transformed enzyme.  
 
In summary, we show that in vitro inhibition kinetics are strongly affected by the 
elemental properties of Au, Pd and Pt. All compounds targeted preferentially the Sec-
residue and potentially converted the enzyme into a pro-oxidant SecTRAP. Cellular 
TrxR1 inhibition was however, strongly dependent on the ligand substituents. 
Additionally, cisplatin mediated the formation of covalently linked complex of TrxR1 
and either Trx1 or TRP14 with yet unknown consequences for the cell.   
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Discussion and future perspectives  
 
These results collectively demonstrated strong elemental differences in TrxR1 targeting 
and inhibition as well as a substantial dependence on the ligand substituent in context 
of cellular uptake and metabolism. The inhibitory effect by Pd together with the 
positive correlation between TrxR1 inhibition and reduction in cell viability identify Pd 
as a promising candidate for the development of a new class of TrxR targeting drugs if 
a suitable ligand substitution can be established. In any case, it would be interesting to 
study the effects of TrxR1 targeting in a more complex system. Many clinically used 
drugs such as auranofin and cisplatin are thought to exhibit part of their function via 
inducing oxidative stress by targeting antioxidant systems. However, a direct 
correlation between specific TrxR1 inhibition and anti-tumor efficacy in a mouse 
model for example was not yet established. 
 
Previous studies that characterized the rapid cell killing effects of SecTRAPs relied on 
protein delivery systems to directly transfer the derivatized enzyme into the cell178, 195. 
This method likely caused a rapid intracellular accumulation of the pro-oxidant enzyme 
form, which in turn influenced the cellular response by promoting rapid and severe 
oxidative stress195. Intracellular SecTRAP formation via drug treatment on the other 
hand might lead to less rapid effects given that the pro-oxidant form accumulates 
probably slower and steadier. Given the slower dynamics, the cells might upregulate 
compensatory antioxidant enzymes that might diminish a cell killing effect. Such a 
situation was previously characterized where a truncated form of TrxR1, which was 
also classified as a SecTRAP195, was overexpressed in cancer cells via DNA 
transfection364. It is thus important for future studies to characterize the dynamics of 
intracellular SecTRAP formation – whether it accumulates fast enough to promote 
efficient cell killing and how the cell reacts to a steady increase in the pro-oxidant form. 
Novel Pd based TrxR1 inhibitors might thus transform the enzyme efficient enough to 
make the difference. 
 
One aspect that we have not looked into, but that might be interesting for future 
mechanistic studies, is the potential influence of the Trx1 or TRP14 attachment on the 
pro-oxidant functions of the cisplatin derivatized enzyme. To know if the NADPH 
Marcus Cebula 
 
44 
oxidase activity is diminished or aggravated might have a huge impact on the SecTRAP 
concept and the design of future compounds and studies. This might not only concern 
stable and DTT resistant complexes such as the cisplatin induced variant, but also 
potential complexes that are sensitive towards DTT reduction while being stable in 
solution. For instance, a truncated TrxR2 variant (missing the Sec residue) was found to 
interact stronger with Trx1 in vitro203. Another study established a crystal structure of 
the TrxR1-Trx1 complex using double mutants of TrxR1 [C497S,U498C] and Trx1 
[C35S,C73S]177, thus showing that non-covalently linked TrxR1:Trx1 complexes may 
be formed independently of cisplatin. Further evidence is presented in paper V, which 
is however, not included in this thesis. We show there that a compromised Sec-residue 
is sufficient for DTT sensitive complex formation. All in all, this shows that further 
research is needed to solidify the concept of a pro-oxidant function of Sec-
compromised TrxR1 in vivo as well as their influences on the cell. 
 
Upon the discovery of TRP14 as component of the cisplatin mediated complexes we 
also aimed to further characterize this yet sparsely studied enzyme. Within paper 4, 
which is not included in this thesis, we characterized its kinetic parameters as substrate 
of TrxR1 and demonstrate that it is an efficient L-cystine reductase and S-denitrosylase. 
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6.3 Paper II 
 
TXNRD1-encoded v3 is targeted to membrane rafts by N-acylation and 
induces filopodia independently of its redox active site integrity. 
Marcus Cebula, Naazneen Moolla, Alexio Capovilla and Elias S. J. Arnér. J Biol Chem. 2013; 288:10002-
10011.  
 
Figure 14. Summary of Paper II. See text for a detailed description. a) The glutaredoxin 
domain of v3 and variants thereof were expressed as GFP-fusion proteins to study the mechanism 
of intracellular localization. b-d) We show that myristoylation at the Gly2 residue targets the 
enzyme to the golgi where it is subsequently palmitoylated at Cys3 and transported to membrane 
raft microdomains as shown via colocalization with the known raft marker CT-B. After performing 
its function, v3 is depalmitoylated and diffuses back to the Golgi where the cycle starts anew. e) At 
the membrane v3 induced the formation of filopodia independently of an intact active site. 
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Results 
 
Intracellular localization of v3 is dependent on myristoylation and palmitoylation at the 
N-terminal MGC-motif  
 
We applied, in accord with previous studies, constructs that express only the 
glutaredoxin domain of v3 in fusion to GFP and variants thereof throughout the whole 
study (Fig. 14a). To our surprise, the intracellular localization pattern and filopodia 
formation were completely independent of an intact -CTRC- active site motif. Instead, 
all features were dependent on the integrity of the N-terminal MGCAEG-sequence, 
which we found to meet the requirements of a myristoylation and palmitoylation site. In 
combination, these two processes form a rather well characterized two-step N-acylation 
that effectively dictates the intracellular sorting and localization of the protein. While 
being newly synthesized, v3 is first co-translationally modified by linking myristic acid 
(C14:0) irreversibly to the N-terminal Gly2 via an amide bond (Fig. 14b1). The 
resulting increase in hydrophobicity serves to promote transient membrane interaction 
that in turn is essential for stable membrane association, subcellular localization and 
protein function365. Myristoylated v3 associates with golgi membranes were it gains 
access to membrane-bound DHHC domain palmitoyltransferases that catalyze the 
addition of palmitic acid (C16:0) to the adjacent cysteine residue at position 3, thus 
further solidifying v3 into the membrane (Fig. 14b2). Palmitoylation is in contrast to 
other lipid modifications reversible and regulated and facilitates subcellular trafficking 
between different membrane compartments366. v3 is as such transported via the 
secretory pathway to its functional site at the plasma membrane (Fig. 14b3). After 
facilitating its task, v3 is depalmitoylated and detaches from this membrane domains 
(Fig. 14b4). The hydrophobicity of myristoyl group guides the protein subsequently 
back to the golgi where the cycle starts anew. These dynamics have been extensively 
characterized by several N-acylated proteins, including Ras, eNos, GAP43, and Giα1367-
369. A particularly neat study characterizes the palmitoylation dependent trafficking 
between Golgi and plasma membrane of H- and N-Ras, which yields a localization 
patterns highly similar to those found here for v3369.  
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In expressing fusion proteins of GFP with either wild type v3 or its G2A and C3S 
mutants, known to impede myristoylation and palmitoylation, we could confirm this 
modifications as only the natural variant was targeted to the plasma membrane. The 
myristoylated, but not palmitoylated C3S variant displayed a strong perinuclear 
staining that is typical for this type of modification whereas the G2A mutant showed a 
cytosolic distribution similar to GFP. These patterns were additionally verified using 
the myristoylation and palmitoylation inhibitors 2-hydroxymyristic acid (2-HMA) and 
2-bromopalmitic acid (2-BPA) (Fig. 14c).  
 
Palmitoylation targets v3 to CT-B positive membrane raft domains 
 
Palmitoylation not only solidifies proteins into membranes, but also facilitates 
subcellular trafficking into membrane subdomains such as lipid rafts366. These 
microdomains are highly dynamic and able to form larger platforms that are thought to 
be stabilized by actin and essential for the assembly of functional complexes and 
signaling events370-372. To examine if v3 localizes into these lipid raft structures as 
consequence of its palmitoylation we performed co-localization studies using cholera 
toxin subunit B (CT-B) as a marker for ganglioside GM1 rich domains. In doing so we 
could verify that the v3 was raft associated and that palmitoylation was a requirement 
(Fig. 14d). Interestingly we also found v3 dimers in purified CT-B positive lipid raft 
fractions indicating that membrane raft patching could have occurred. The induction of 
filopodia has indeed already been linked to membrane raft stimulation and patching in 
previous studies373-375. Thus a potential explanation is that actin polymerization and 
filopodia formation is induced as a means to stabilize raft platforms with are formed 
due to the extensive v3 accumulation (Fig. 14e). 
 
In summary, we found that v3 is myristoylated and palmitoylated at its N-terminal 
motive. As a consequence it is targeted to CT-B positive membrane rafts where it 
correlates with the induced formation of filopodia. All observed features were 
independent of an intact -CTRC- motif and the presence of the TrxR1 core module.  
Its functions are yet unknown, but the here identified membrane raft association of the 
v3 splice variant of TrxR1 clearly expands the spectrum of the Trx system. 
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Discussion and future perspectives 
 
Potential impact of N-acylation on the catalytic activity of v3 in relation to previous 
studies 
 
The catalytic activity of recombinant v3 was previously characterized by Gladyshev et 
al., showing that the enzyme was unable to use Trx1 as substrate, but could efficiently 
reduce DTNB208. A truncated variant, missing the last two amino acids (Sec-Gly) 
displayed a similar activity as the Sec-containing enzyme, which is in strong contrast to 
TrxR1 where DTNB reduction is considered highly Sec-dependent. Interestingly, a 
similar behavior was reported for TGR that has a monothiol Grx domain as N-terminal 
to a thioredoxin reductase core module, thus indicating that the N-terminal domains 
have a strong influence on the catalytic mechanism and that both enzymes potentially 
share similarities in their catalytic mechanisms199. In contrast to v3, TGR was able to 
reduce Trx1 and also showed typical Grx activity – a property that v3 only gained after 
its unusual -CTRC- active site was mutated to the more common -CPYC- motif found 
in glutaredoxins208.  
 
However, these properties need to be potentially re-evaluated. The acylated, lipophilic 
N-terminal renders a homodimer with a symmetric head-to-tail confirmation of two 
identical v3 subunits unlikely as both opposite ends are unable to attach to the 
membrane simultaneously. It is thus reasonable to assume that v3 is either present as 
monomer or that it might form a heterodimer with only one subunit being v3 and the 
other the main variant of TrxR1. A monomeric form would be uncommon, but not 
implausible. It was for instance demonstrated that the monothiol active site motif of the 
Grx domain in TGR was able to receive electrons from either the thioredoxin reductase 
domain of TGR or TrxR1199. A dimer, consisting of the main TrxR1 variant and v3, 
might be also able to efficiently reduce Trx1 and exhibit a different catalytic profile 
than reported so far.  
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Potential functions at membrane rafts  
 
In general, it would be of major interest to further probe potential functions and 
substrates of v3. The membrane raft association locates v3 in close proximity to several 
redox systems and proteins involved in signaling such as NOX, eNOS, Src family 
kinases, phosphatases, cytoskeleton-binding proteins and many more371, 372. The 
activity and function of several of those is regulated via reversible oxidative 
modifications. For instance, NOX mediated superoxide production is stimulated by 
EGF, PDGF and insulin-receptor signaling. The resulting ROS promotes in turn 
oxidation of redox sensitive proteins such as Prxs, kinases and PTPs as well as their 
downstream signaling events, thus affecting numerous cellular processes such as 
differentiation, proliferation and migration269, 273, 376, 377 (see Fig. 16 in summary 
section 6.5). v3 might in this setup potentially act as a local regulator of certain growth 
factor or hormone stimulated events via reactivation of certain PTPs or peroxiredoxins 
or via reduction of kinases such as Src. Previous studies have already shown that the 
Trx system catalyzes the efficient reduction of several peroxiredoxins as well as of 
PTPs such as PTP1B, PTEN as well as Cdc25A and B258, 277, 377-380. Interestingly, Grx 
was also shown to reduce PTP1B377 as well as LMW-PTP, suggesting that the Grx 
domain of v3 might be able to mediate similar functions381.  
 
It shall be emphasized again that v3 was in previous studies not able to reduce Trx1 nor 
was its Grx domain active in typical assays whereas it should not be involved in the just 
mentioned processes. However, as illustrated above, v3 might exhibit a different 
catalytic profile if expressed in mammalian cells compared to the studies using 
recombinantly expressed enzyme. Alternatively, v3 might also reduce certain substrates 
either directly or via Trx-like proteins such as TRP14, which was also not studied yet. 
 
Intriguing possibilities for v3 function reminiscent to the close correlation with actin 
are podosomes and invadopodia. These are actin rich invasive microdomains that are 
specialized for matrix degradation and potentially important for metastasis and cell 
movement through the matrix. They are formed by cancer and normal cells, 
respectively. Initiation, maturation and regulation of this structures is complex and 
involves numerous factors including growth factor and adhesion signaling, NOX 
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activation, PTP oxidation, kinases activation, actin regulatory elements, membrane rafts 
and many more382. Extensive ROS production is considered to be essential for these 
structures, but the regulation of redox processes is yet only sparsely analyzed85, 383. v3 
function within specialized structures such as podosomes and invadopodia might also 
explain its general low abundance. 
 
Potential future experiments 
 
All evidence so far describes v3 as a rare enzyme. The regulation of its expression is 
only sparsely characterized on mRNA as well as protein level. Its presumably low 
expression levels are a major handicap for functional studies, whereas most studies 
need to rely on DNA transfection and overexpression. This is a general problem of low 
abundant membrane proteins and much effort is required to optimize detection 
methods384.  
 
Potential future experiments might involve overexpression of the Sec-containing full 
length v3 and mutants thereof in mammalian cells with subsequent growth factor or 
hormone stimulation while studying the cellular response. This approach might also be 
combined with the pTRAF methodology as described in Paper III to characterize the 
potential impact on the activation of transcription factors. Single active site mutants 
may be used to trap and identify potential binding partner. To distinguish v3 from other 
TrxR1 variants one can either use antibodies raised against the unique Grx domain or 
implement a FLAG-tag ca. 10-20 amino acids away from the N-acylation site. The 
characterization of the alternative v3 promoter as well as the expression of the 
endogenous variant on mRNA and protein level in relation to different cell types may 
also be further pursued.  
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6.4 Paper III 
 
Simultaneous Determination of Nrf2, HIF and NFκB Activation at Single-
Cell Resolution. 
Katarina Johansson, Marcus Cebula, Olle Rengby, Kristian Dreij, Kristmundur Sigmundsson, Elias S. J. 
Arnér. Manuscript. 
 
 
 
Figure 15. Summary of Paper III. See text for a detailed description. a) We constructed, 
characterized and utilized the pTRAF plasmid to analyze Nrf2, HIF and NFB activation in 
response to various stimuli by measuring corresponding fluorescent signals on single cell level. 
The fluorescence intensities are analyzed as either b) an accumulated signal to display the total 
response of all cells or in c) single cell distribution plots to show the stochastic degree of the 
events. The data in the scheme were acquired at 1% oxygen tension.  
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Results 
 
Construction and validation of the pTRAF method 
 
We developed a method that utilizes fluorescent proteins to monitor the activation of 
three separate transcription factors. For this we constructed a single reporter plasmid 
(pTRAF: plasmid for transcription factor reporter activation based upon fluorescence) 
that carries three separately transcribed “response element - fluorescent protein” 
combinations. This arrangement enables the simultaneous analysis of their intertwined 
regulation within a single cell without the need of a separate transfection control. 
 
As a proof of principle we tested this system on the three major transcription factors 
Nrf2, HIF and NFB that are all in part regulated by the Trx and GSH systems and 
involved in different pathological conditions such as cancer, chronic inflammation as 
well as cardiovascular and degenerative diseases. This particular pTRAF variant thus 
carried the following cassettes: “Nrf2 - mCherry (red)”, “HIF - YPet (yellow)” and 
“NFB - CFP (cyan)” (Fig. 15a). For validation we stimulated pTRAF transfected 
HEK293 cells with the known Nrf2 and NFκB inducing drugs auranofin and TNFα at 
1% and 21% oxygen tension and compared the results with traditional luciferase 
assays. The results agreed well at an accumulated cell-culture level with pTRAF having 
the advantage of a simultaneous analysis whereas the luciferase approach required three 
separate experiments (Fig. 15b). We also verified that pTRAF does not alter the regular 
cellular response by quantifying transcripts of known downstream target genes for Nrf2, 
HIF or NFκB using quantitative PCR and comparing the result to non-transfected cells.  
 
Validation of the pTRAF method for high throughput applications 
 
To further characterize the performance of pTRAF, specifically to validate its usability 
for high throughput applications, we included several additional treatments and 
analyzed the corresponding transcriptional responses of Nrf2, HIF and NFB using the 
Operetta® high-content imaging system. The results were highly reproducible and led 
to interesting observations. The combinatory treatment of doxorubicin and TNFα for 
instance stimulated a strong synergistic NFB activation that was much higher than for 
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TNFα alone, whereas doxorubicin gave no NFB activation by itself. Another 
interesting observation was the effect on HIF activation with a number of non-classified 
HIF inducers including those that activated NFB (Fig. 15b).  
 
The main advantage of using pTRAF however, is the ability to validate the activation 
of all three transcription factors within each cell separately based on the arrangement of 
all cassettes being located on the same plasmid. Thus by comparing the intensities of 
mCherry, YPet and CFP to each other it is possible to study the relative activation of all 
three transcription factors in single cells without the need to control for transfection. 
We visualized these data by plotting the cells of a whole culture in a triangular plot. 
The resulting pattern shows the treatment dependent distribution of single cell 
transcription factor activities and thus the level of stochastic cellular events (Fig. 15c). 
A potential improvement that would be beneficial if implemented might be to quantify 
the stochastic degree to be able to better compare various treatments.  
 
In summary, we developed and validated the pTRAF method for the simultaneous 
analysis of three different transcription factors on single cell level. We initially focused 
on Nrf2, HIF and NFκB responses, but the methodology can also be adapted to other 
combinations of three response elements. 
 
Discussion and future perspectives 
 
Based on these preliminary, but very encouraging results, we aim to further improve 
the pTRAF method and to expand the scope of its applications. The main aspect that 
we wish to follow up is to apply this tool to study how Nrf2, HIF and NFκB are 
intertwined and regulated on single cell level. A potential approach could involve the 
combination with additional methods. For instance may cells with a specific response 
pattern be separated via FACS and subsequently analyzed regarding their unique 
mRNA or protein composition in order to understand why they respond the way they 
did. 
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Improvements on the pTRAF methodology 
 
The fluorescent proteins mCherry, YPet and CFP were chosen as they are stable, 
monomeric proteins with a high quantum yield and a short maturation time while 
enabling an optimal separation between the channels. However, the high demand on 
suitable fluorescent proteins for imaging pushes the development of more suitable 
variants constantly forward. For example, a highly improved cyan fluorescent protein, 
termed mTurquoise2, was recently developed that might strongly improve the signal-
to-noise ration when analyzing NFB activation with pTRAF385. Other examples are 
given by far red and near-infrared fluorescent proteins386. They might be more suitable 
than mCherry depending on the technical specifications of the setup as the suitable 
margin for optimal excitation and emission is increased.   
 
So far experiments relied on transient transfection to transfer the pTRAF plasmid with 
an approximate efficiency of 50% into the cells. To achieve either higher transfection 
rates or to be completely independent on transient transfection procedures altogether 
we wish to develop a viral transfection routine and to establish a cell line that has the 
pTRAF plasmid incorporated into its genome.  
 
An alternative approach in using pTRAF is to exchange one response element with a 
constitutively active promoter. This specific variant would give the possibility to set the 
activation of the two remaining transcription factors in relation to a well established and 
characterized promoter, thus enabling to further quantify the absolute response of a 
single cell. In addition we also wish to further implement different response elements. 
For instance would it be also of interest to monitor p53 or c-Myc in cancer cells for 
instance. 
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6.5 Summary and conclusion 
 
Within this thesis we investigated different aspects of the Trx system in the context of 
redox signaling with Figure 16 giving a graphical summary that combines all three papers 
in the cellular context. 
 
In Paper I we focused as such on the inhibition of TrxR1 by noble metal based drugs and 
showed that all used compounds efficiently targeted the Sec-residue and thus potentially 
transformed the enzyme into its pro-oxidant SecTRAP form. This transformation not only 
diminishes all antioxidant and redox regulatory downstream functions such as those 
mediated by Trx1 or TRP14, but also promotes additional ROS formation by its attained 
NADPH oxidase activity. The increased ROS levels in turn may cause random oxidative 
damage, trigger apoptosis via ASK1 release from oxidized Trx1 or promote various 
response pathways such as stress adaptation by activating Nrf2, which leads to a boost of 
the Trx- and GSH-systems inter alia (Fig. 16 I). This differential response to TrxR1 
inhibition is indeed favorably for anti-cancer therapy – healthy cells may be protected by 
the concomitant Nrf2 response while cancer cells that are already at their anti-oxidant limit 
will rather suffer from a further increase in ROS by oxidative damage and cell death 
pathway induction. Further studies, particularly in more complex systems such as mouse 
models, are clearly needed. Nonetheless, may the specific, drug based inhibition of TrxR be 
a clear asset for the future treatment of certain conditions such as cancer.     
 
In Paper II we further expanded the functional spectrum of the Trx system in 
demonstrating that the v3 splice variant of TrxR1 associates with lipid raft microdomains, 
which have been shown to serve as redox signaling platforms. Despite its yet unknown 
functions, v3 is potentially involved in the regulation of specific redox dependent 
processes. It might for instance play a role in cell surface receptor mediated signaling, 
which includes kinase activation and local H2O2 formation via NOXs. The H2O2 production 
in the vicinity of the receptor modulates the activities of certain PTPs and kinases to enable 
proper downstream signaling as for example in case of MAPK pathway mediated gene 
expression, NFκB activation as well as a myriad of other processes (Fig. 16 II). v3 might 
regulate the redox status of a number of enzymes in this setup either directly via its unique 
Grx domain or through redoxins such as Trx1 or TRP14.  
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The Trx- and GSH-systems are furthermore directly or indirectly involved in the redox 
regulation of transcription factors such as Nrf2, HIF or NFκB. For example, Trx1 promotes 
the transactivation in the nucleus by reducing crucial cysteine residues in these 
transcription factors. In the cytosol, Trx1 may diminish the activation of Nrf2, NFB by 
regulating H2O2, whereas it promotes HIF activation by stimulating its translation. An 
example is given by TRP14, a Trx-like substrate of TrxR1 that was previously reported to 
reduce the LC8 chain, which binds and protects IκB from phosphorylation and prevents 
thus NFκB from being activated (Fig. 16 III). The overall mechanisms by which redox 
regulation of transcription factors is mediated in general and by the Trx-system in 
particular, is however, still largely unknown and thus one of the key intention behind the 
study in Paper III. Furthermore, several transcription factors are functionally intertwined. 
NFκB activation that is stimulated via receptor signaling also activates HIF. This 
transcription factor is typically induced by low oxygen levels – a condition which may 
affect ROS production and thus the redox state of key elements within other signaling 
pathways such as Nrf2 or NFκB activation. Nrf2 activation that is typically mediated by 
oxidative stress or via reactive electrophiles, promotes furthermore the transactivation of 
antioxidant and detoxifying enzymes, including components of the Trx-and GSH-systems. 
The upregulation of these systems affects in turn the redox regulation within the cell and is 
for instance considered to mediate the downregulation of NFκB. In constructing pTRAF 
within Paper III we developed a tool that enables us to monitor the activation of three 
transcription factors simultaneously within a single cell in order to study their intertwined 
activation pathways.      
  
In conclusion, we expanded the functional spectrum of the Trx-system to lipid rafts, 
showed that TrxR1 can be efficiently targeted by electrophilic compounds that potentially 
convert the enzyme into its pro-oxidant SecTRAP form and developed a tool that enables 
simultaneous determination of three transcription factor activities within single cell level to 
study their functional interplay.   
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Figure 16. Schematic overview of Paper I to III in relation to the Trx-system. Roman 
numerals indicate the various aspects of the three papers. See text for further details.  
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